<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/316455</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Microbiology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluation of current and emerging anti-malarial medicines for inhibition of <italic>Toxoplasma gondii</italic> growth in vitro</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Radke</surname>
<given-names>Joshua B.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Burrows</surname>
<given-names>Jeremy N.</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goldberg</surname>
<given-names>Daniel E.</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7110-0285</contrib-id>
<name>
<surname>Sibley</surname>
<given-names>L. David</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Department of Molecular Microbiology, Washington University Sch. Med</institution>., St Louis, MO 63110</aff>
<aff id="a2"><label>2</label><institution>Medicines for Malaria Venture</institution>, ICC, Route de Pr&#x00E9;-Bois 20, 1215 Geneva, <country>Switzerland</country></aff>
<aff id="a3"><label>3</label><institution>Departments of Medicine and Molecular Microbiology, Washington University Sch.Med</institution>., St Louis, MO 63110</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Corresponding Author: L. David Sibley (<email>sibley@wustl.edu</email>)</corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2018</year>
</pub-date>
<elocation-id>316455</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>07</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>5</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="316455.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p><italic>Toxoplasma gondii</italic> is a common zoonotic infection of humans and estimates indicate that 1-2 billion people are chronically infected. Although largely asymptomatic, chronic infection poses risk of serious disease due to reactivation should immunity decline. Current therapies for toxoplasmosis only control acute infection caused by actively proliferating tachyzoites but do not eradicate the chronic tissue cyst stages. As well, there are considerable adverse side effects of the most commonly used therapy of combined sulfadiazine and pyrimethamine. Targeting the folate pathway is also an effective treatment for malaria, caused by the related parasites <italic>Plasmodium</italic> spp., suggesting common agents might be used to treat both infections. Here we evaluated currently approved and newly emerging medicines for malaria to determine if such compounds might also prove useful for treating toxoplasmosis. Surprisingly, the majority of anti-malarial compounds being used currently or in development for treatment of malaria were only modestly effective at inhibiting in vitro growth of <italic>T. gondii</italic> tachyzoites. These findings suggest that many essential processes in <italic>P. falciparum</italic> that are targeted by anti-malarial compounds are either divergent, or non-essential in <italic>T. gondii</italic>, thus limiting options for repurposing of current antimalarial medicines for toxoplasmosis.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Key words</title>
<kwd>Medicines for Malaria Venture</kwd>
<kwd>Apicomplexa</kwd>
<kwd>antibiotics</kwd>
<kwd>chronic infection</kwd>
<kwd>bradyzoite</kwd>
<kwd>latency</kwd>
</kwd-group>
<counts>
<page-count count="28"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p><italic>Toxoplasma gondii</italic> is a common parasite of animals that causes zoonotic infections in humans. It has diverged from its closest relatives by adopting a broad host range re-enforced by flexible modes of transmission (<xref ref-type="bibr" rid="c1">1</xref>). <italic>Toxoplasma gondii</italic> is transmitted by cats, where sexual reproduction in the intestine results in shedding of highly resistant oocysts into the environment (<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c3">3</xref>). Ingestion of oocysts by rodents, and many other intermediate hosts, results in acute infection that is characterized by initial expansion of a fast growing tachyzoite form that disseminates widely throughout the body. Following a vigorous immune response the parasite differentiates into a slow growing, semi-dormant form called the bradyzoite, which inhabits tissue cysts in the muscle and brain (<xref ref-type="bibr" rid="c4">4</xref>-<xref ref-type="bibr" rid="c6">6</xref>). Human infections are acquired by ingestion of oocysts that contaminate food or water, or by eating undercooked meat that harbors tissue cysts. <italic>Toxoplasma gondii</italic> is a significant cause of serious food borne infection in the USA (<xref ref-type="bibr" rid="c7">7</xref>), and it has also been associated with waterborne outbreaks in North and South America (<xref ref-type="bibr" rid="c8">8</xref>). Global serological studies indicate that &#x007E;25&#x0025; of humans are chronically infected, although prevalence rates vary widely in different locations (<xref ref-type="bibr" rid="c7">7</xref>). Most human infections with <italic>T. gondii</italic> are relatively benign, although they are persistent, as the chronic stages of infection (i.e. bradyzoites within tissue cysts) are not eliminated by the immune response. Additionally, toxoplasmosis can cause serious disease due to congenital infection (<xref ref-type="bibr" rid="c9">9</xref>) and in immuncompromised patients (<xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c11">11</xref>). Additionally, even healthy adults are at risk due to highly pathogenic strain types that are found some regions such as South America (<xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>).</p>
<p>Toxoplasma is a member of the phylum Apicomplexa, a group of more than 10,000 known species, most of which are parasitic (<xref ref-type="bibr" rid="c14">14</xref>). Other apicomplexan parasites of medical importance include <italic>Plasmodium</italic> spp., the causative agent of malaria (<xref ref-type="bibr" rid="c15">15</xref>), and <italic>Cryptosporidium</italic> spp., a frequent cause of severe diarrheal disease in young children in developing countries (<xref ref-type="bibr" rid="c16">16</xref>). Apicomplexans are most closely related to ciliates and dinoflagellates, but only distantly related to humans, hence they share many key differences from their hosts (<xref ref-type="bibr" rid="c17">17</xref>). Although members of the phylum Apicomplexa span 400 mya of evolution (<xref ref-type="bibr" rid="c18">18</xref>), they contain many orthologous genes and much of their biology is conserved (<xref ref-type="bibr" rid="c19">19</xref>). Among their similar features, <italic>Plasmodium</italic> and <italic>Toxoplasma</italic> contain intact pathways for pyrimidine biosynthesis, while they are purine auxotrophs, and these pathways have been the focus of development of inhibitors to combat both infections (<xref ref-type="bibr" rid="c20">20</xref>).</p>
<p>Current therapies for treatment of toxoplasmosis rely primarily on inhibition of the folate pathway in the parasite, although antibiotics developed for treating bacterial infections have also been used with some success (<xref ref-type="bibr" rid="c21">21</xref>, <xref ref-type="bibr" rid="c22">22</xref>). The most commonly used treatment is a combination of sulfa drugs with pyrimethamine (i.e. sulfadiazine and pyrimethamine or trimethoprim with sulfamethoxazole). This combination is highly synergistic as the sulfa drug inhibits dihydropteroate synthase (DHPS) while pyrimethamine inhibits dihydrofolate reductase (DHFR), together disrupting tetrahydrofolate levels and blocking DNA synthesis. The combination of pyrimethamine and sulfa drugs is highly effective in blocking replication of tachyzoites but has no activity on bradyzoites within tissue cysts and therefore does not eliminate chronic infection (<xref ref-type="bibr" rid="c23">23</xref>). As well, there are significant adverse effects of this treatment regime due to intolerance or allergic reaction to the sulfa component and bone marrow suppression that requires co-administration of leucovorin (<xref ref-type="bibr" rid="c24">24</xref>, <xref ref-type="bibr" rid="c25">25</xref>). Additionally, due to potential for inducing developmental defects, this combination is contraindicated during the first two trimesters of pregnancy, but can be effective in reducing clinical severity when given in the third trimester (<xref ref-type="bibr" rid="c26">26</xref>). Although alternative therapies such as clindamycin, azithromycin, and other antibiotics, have also been used to treat acute toxoplasmosis, they also do not clear chronic infection (<xref ref-type="bibr" rid="c21">21</xref>).</p>
<p>There have been several efforts to identify new drugs for toxoplasmosis based on FDA-approved drugs. Screening of FDA approved drugs has revealed several inhibitors of tachyzoite growth in vitro, most of which were initially developed to treat inflammation (<xref ref-type="bibr" rid="c27">27</xref>). Guanabenz, which targets alpha-2 adrenergic receptors and is used for hypertension, additionally shows efficacy in mouse models of toxoplasmosis (<xref ref-type="bibr" rid="c28">28</xref>, <xref ref-type="bibr" rid="c29">29</xref>). Finally, treatment of infected cells with tamoxifen, an inhibitor of the estrogen receptor, leads to parasite clearance due to an autophagy-related process (<xref ref-type="bibr" rid="c30">30</xref>). Although such compounds provide promising leads, they do not allow selective inhibition of the parasite since they were originally optimized to modulate host processes. Hence, there is a need for new treatments that are more selective, less toxic, and effective at eliminating chronic infection by <italic>T. gondii</italic>.</p>
<p>One potential source for new drugs to treat toxoplasmosis would be repurposing of medicines that have been developed for malaria, a concept that is based on their shared ancestry and similar biology. One example is the use of pyrimethamine-sulfa drug combinations to treat toxoplasmosis. Similarly, Fansidar (sulfadoxine and pyrimethamine) was historically effective against <italic>P. falciparum</italic>. However, due to the global spread of anti-folate (<xref ref-type="bibr" rid="c31">31</xref>) and chloroquine resistance (<xref ref-type="bibr" rid="c32">32</xref>), the first line of treatment for malaria has shifted to the natural product artemisinin, which is a sequiterpene lactone that contains an endoperoxide bridge that is key to its activity (<xref ref-type="bibr" rid="c33">33</xref>). A number of semi-synthetic variants have been produced including artesunate, artemether, and artemisone, which are more soluble prodrug forms that are rapidly converted to dihydroartemisinin in plasma (<xref ref-type="bibr" rid="c31">31</xref>). Artemisinin derivatives also inhibit replication of <italic>T. gondii</italic> in vitro (<xref ref-type="bibr" rid="c34">34</xref>-<xref ref-type="bibr" rid="c36">36</xref>) and are partially effective in murine infection models, although they do not eliminate chronic infection (<xref ref-type="bibr" rid="c37">37</xref>, <xref ref-type="bibr" rid="c38">38</xref>).</p>
<p>Considerable effort has been expended to develop new generation anti-malarials based on large-scale phenotypic high throughout screens (HTS) for inhibition of asexual blood stage forms of <italic>P. falciparum</italic> (<xref ref-type="bibr" rid="c39">39</xref>). A number of the resulting hits were prioritized by the Medicines for Malaria Venture (MMV) based on chemical properties as well as activity to define a core set of compounds for inclusion in the Malaria Box and Pathogen Box projects (<ext-link ext-link-type="uri" xlink:href="https://www.pathogenbox.org/">https://www.pathogenbox.org/</ext-link>). Combined with genomic analyses of evolved resistant mutants, these screening efforts have led to identification of new leads that target essential steps in the parasite (<xref ref-type="bibr" rid="c39">39</xref>). One of the first new active malarial compounds to be identified by a screening/genomics approach was the class of compounds known as spiroindolones (<xref ref-type="bibr" rid="c40">40</xref>), including the analog KAE609 that proved effective in curing mice of <italic>P. berghei</italic> infection with a single oral dose (<xref ref-type="bibr" rid="c41">41</xref>). Whole genome sequencing of resistant mutants, and subsequent genetic confirmation, indicated that spiroindolones target the cation transporter PfATP4 (<xref ref-type="bibr" rid="c42">42</xref>), thereby disrupting sodium transport in the parasite (<xref ref-type="bibr" rid="c43">43</xref>). A similar strategy of whole genome sequencing of resistant mutants has led to the identification of several tRNA synthases as targets of potent antimalarial candidate compounds and mutations in the PfCarl (cyclic amine resistance locus) gene that medicates resistance to potent imidazolopiperizines (<xref ref-type="bibr" rid="c39">39</xref>).</p>
<p>The availability of the Malaria and Pathogen Box (<ext-link ext-link-type="uri" xlink:href="https://www.pathogenbox.org/">https://www.pathogenbox.org/</ext-link>) collections has made it possible to expand the analysis of these compounds to other pathogens (<xref ref-type="bibr" rid="c44">44</xref>). Analysis of compounds in the Malaria Box for inhibition of in vitro growth of <italic>T. gondii</italic> identified seven compounds with EC<sub>50</sub> &#x2264; 5 &#x03BC;M including a piperazine acetamide with an EC<sub>50</sub> &#x003C; 0.19 uM (<xref ref-type="bibr" rid="c45">45</xref>). The hit rate of &#x007E; 2&#x0025; observed in this study is higher than typically seen in typical HTS; however, it might be considered low based on the premise that <italic>T. gondii</italic> and <italic>P. falciparum</italic> are members of the same phylum and share much of their underlying biology. Several of the active compounds contain a quinolone moiety, suggesting they may be active due to their resemblance to endochin-like quinolones (<xref ref-type="bibr" rid="c46">46</xref>) and atovaquone (<xref ref-type="bibr" rid="c47">47</xref>), which act on the bc1 complex and that are active against <italic>T. gondii</italic>. A second study that also employed the Malaria Box reported a much higher hit rate, with 49 compounds out of &#x007E;400 showing EC<sub>50</sub> values &#x2264; 1 &#x03BC;M when tested for inhibition of tachyzoite growth in vitro (<xref ref-type="bibr" rid="c48">48</xref>); the difference in hit rate being attributed to methodology. Although a number of these compounds were also inhibitors of <italic>P. falciparum</italic>, the overall correlation in potency between these two parasites was low (<xref ref-type="bibr" rid="c48">48</xref>). A similar screen for tachyzoite in vitro growth inhibition by compounds in the Pathogen Box identified four compounds with EC<sub>50</sub> values &#x2264; 1.0 &#x03BC;M and selectivity indices of &#x003E; 4 (<xref ref-type="bibr" rid="c49">49</xref>). Among the more potent compounds identified was buparvaquone, which is a naphthoquinone that also inhibits mitochondrial electron transport. This study also reported that many compounds active against <italic>Plasmodium</italic> did not show appreciable inhibition of <italic>T. gondii</italic>.</p>
<p>To complement previous efforts that have focused on the early preclinical leads found in the Malaria and Pathogen Box collections, we focused here on approved medicines for malaria, new anti-malarial candidates or emerging leads that are in the global malaria portfolio, many of which with Medicines for Malaria Venture (MMV) (<xref ref-type="bibr" rid="c39">39</xref>, <xref ref-type="bibr" rid="c50">50</xref>). Many of these compounds show excellent potential for treatment of malaria, and have advanced through a number of preclinical safety checks and in some cases clinical studies, and include a number of currently used medicines. The rationale for this project was that if active compounds were found among this set, they might be readily repurposed for treatment of toxoplasmosis or give information on biological pathways to target in <italic>T. gondii</italic>.</p>
</sec>
<sec id="s2">
<title>Results and Discussion</title>
<p>We tested 81 compounds including a number of current medicines used for treatment of malaria and candidates that are in late preclinical development or undergoing current clinical trials. Although some individual compounds had been tested on <italic>T. gondii</italic> previously, many are new compounds and this represents the first time this set of compounds has been compared side by side in the same assay. We tested them in parallel using a multi-well plate assay that monitors in vitro growth of <italic>T. gondii</italic> tachyzoites based on firefly luciferase expression. Initially, we evaluated each of the compounds at a single concentration (10 &#x03BC;M) in triplicate assays to define those that showed &#x003E; 50 &#x0025; growth inhibition. Based on this cutoff, 52 compounds were chosen for further analysis based on duplicate 10-point dilution series that were used to define the EC<sub>50</sub> values for growth inhibition. Results of the screen are summarized in <xref ref-type="table" rid="tbl1">Table 1</xref> and <xref ref-type="fig" rid="fig1">Figure 1</xref>, where compounds are ranked by relative potency.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<title>Sumary of EC<sub>50</sub> values for inhibtion of <italic>T. gondii</italic> growth in vitro</title>
</caption>
<graphic xlink:href="316455_tbl1.tif"/>
</table-wrap>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1</label>
<caption>
<p>Rank order of compounds in terms of EC<sub>50</sub> values for inhibition of <italic>T. gondii</italic> tachyzoite growth in vitro. Values represent mean of two independent 10-point titrations that were used to derive EC<sub>50</sub> values by doseresponse curve fits (see methods). Compounds of interest are highlighted including pyrimethamine (red dot), artemisinin and related compounds (yellow), inhibitors of PfATP4 (orange), and antibiotics (green). See <xref ref-type="table" rid="tbl1">Table 1</xref> for complete EC<sub>50</sub> values.</p>
</caption>
<graphic xlink:href="316455_fig1.tif"/>
</fig>
<p>Among the set of 52 compounds, 18 of them showed EC<sub>50</sub> values of &#x003C; 1 &#x03BC;M, including pyrimethamine (<xref ref-type="fig" rid="fig1">Figure 1</xref>, red dot), consistent with previously reported values for the activity of this DHFR inhibitor on growth of <italic>T. gondii</italic> in vitro (<xref ref-type="bibr" rid="c51">51</xref>, <xref ref-type="bibr" rid="c52">52</xref>). Other inhibitors of DHFR were considerably less potent, including methotrexate (<xref ref-type="bibr" rid="c53">53</xref>, <xref ref-type="bibr" rid="c54">54</xref>) and cycloguanil (<xref ref-type="bibr" rid="c55">55</xref>, <xref ref-type="bibr" rid="c56">56</xref>), consistent with previous reports (<xref ref-type="table" rid="tbl1">Table 1</xref>). As expected, sulfa drugs were also less potent including sulfadiazine, sulfamethoxoazole, and dapsone (<xref ref-type="table" rid="tbl1">Table 1</xref>), consistent with previous reports of their in vitro activity (<xref ref-type="bibr" rid="c52">52</xref>, <xref ref-type="bibr" rid="c57">57</xref>, <xref ref-type="bibr" rid="c58">58</xref>). The low activity of these molecules vitro may reflect high levels of <italic>p</italic>-araminobenzoic acid in culture medium, as this metabolite acts competitively with these inhibitors of DHPS. Although sulfa drugs are not effective when used alone, as part of the current combination therapy they are highly synergistic with pyrimethamine (<xref ref-type="bibr" rid="c52">52</xref>, <xref ref-type="bibr" rid="c59">59</xref>). Among the potent compounds that have not been reported previously was methylene blue, a phenothiazin dye that is being evaluated as a transmission blocking compound for malaria (<xref ref-type="bibr" rid="c50">50</xref>). Also included among the most actives were several antibiotics that target prokaryotic protein synthesis by disrupting ribosomes including the lincosamides clindamycin and mirincamycin, and the macrolide azithromycin (<xref ref-type="table" rid="tbl1">Table 1</xref>). Interesting, although doxycycline was active in inhibiting <italic>T. gondii</italic> growth, tetracycline showed almost no activity, consistent with a previous report (<xref ref-type="bibr" rid="c60">60</xref>). A number of antibiotics have previously been shown to be active on <italic>T. gondii</italic> (<xref ref-type="bibr" rid="c59">59</xref>, <xref ref-type="bibr" rid="c61">61</xref>-<xref ref-type="bibr" rid="c64">64</xref>) and their mechanism of action is likely due to inhibition of protein synthesis in the apicoplast (<xref ref-type="bibr" rid="c65">65</xref>). The main limitation to use of broad-spectrum antibiotics for treatment of toxoplasmosis is their potent activity on the endogenous bacterial flora in the microbiome leading to disbiosis and gastrointestinal distress, thus increasing the risk of <italic>C. difficile</italic> infection (<xref ref-type="bibr" rid="c66">66</xref>). The use of such agents that target bacteria also increases the risk of unwanted emergence of resistance among other classes of pathogens.</p>
<p>Other potent inhibitors include the endochin-like quinolone ELQ-300 that targets the Qi site in the cytochrome bc1 complex (<xref ref-type="bibr" rid="c67">67</xref>) and atovaquone that targets the Qo site (<xref ref-type="bibr" rid="c68">68</xref>) in the cytochrome bc1 complex of the mitochondrial respiratory chain (<xref ref-type="table" rid="tbl1">Table 1</xref>). Previous studies have shown that atovaquone is effective in blocking <italic>T. gondii</italic> replication in vitro and in reducing cyst numbers in chronically infected mice (<xref ref-type="bibr" rid="c52">52</xref>, <xref ref-type="bibr" rid="c62">62</xref>), as well as suppressing reactivation of chronic infection in an immunocomprmised mouse model (<xref ref-type="bibr" rid="c69">69</xref>). However, prior experience with atovoquone in humans with toxoplasmosis includes several examples of therapeutic failure (<xref ref-type="bibr" rid="c47">47</xref>, <xref ref-type="bibr" rid="c70">70</xref>), possibly due to resistance arising, although the mechanism was not confirmed at the molecular level. Similar to atovoquone, ELQ-300 is potent in inhibiting parasite growth in vitro and in reducing cyst numbers in the brains of chronically infected mice (<xref ref-type="bibr" rid="c46">46</xref>). The main issue with ELQ-300 (<xref ref-type="bibr" rid="c46">46</xref>), and related quinolone compounds (<xref ref-type="bibr" rid="c71">71</xref>), is their low solubility that reduces oral bioavailability. Consequently, efficacy trials in murine models of toxoplasmosis have relied on parenteral administration of the compounds. This limitation has been partially mitigated by production of esterified pro-drugs that get activated in vitro, allowing for oral treatment that was protective in a mouse model for <italic>P. yoelli</italic> (<xref ref-type="bibr" rid="c72">72</xref>). Given that multiple quinolone containing compounds that affect mitochondrial electron transport are active against <italic>T. gondii</italic>, including against bradyzoites in tissue cysts, this pathway remains an important target for further investigation.</p>
<p>Drugs that have traditionally been used to treat malaria were much less potent in inhibiting <italic>T. gondii</italic> including both 4-amino and 8-amino quinolines (<xref ref-type="table" rid="tbl1">Table 1</xref>). Chloroquine and a variety of related 4-aminoquniolines are active against asexual parasite stages of <italic>Plasmodium</italic> that replicate in red blood cells, where these compounds are thought to inhibit hemozoin formation within the parasite&#x2019;s digestive food vacuole (<xref ref-type="bibr" rid="c73">73</xref>). Among this class of compounds, bisquinoline and benzylquine were the most active with EC<sub>50</sub> values of less than 1 &#x03BC;M, while other derivatives were less potent against <italic>T. gondii</italic> (<xref ref-type="table" rid="tbl1">Table 1</xref>). These compounds are thought to target hemozoin formation during hemoglobin degradation in <italic>Plasmodium</italic> (<xref ref-type="bibr" rid="c73">73</xref>), and the lack of an analogous digestive pathway in <italic>T. gondii</italic> may explain the lack of potency of most members of this class. However, the fact that several 4-amino quinolones and 4-anilino compounds (i.e. pyronaridine, amodiaquine) showed modest potency in inhibiting <italic>T. gondii</italic>, suggests that they target another important process (<xref ref-type="table" rid="tbl1">Table 1</xref>).</p>
<p>A number of 8-aminoquinolones are also effective for treatment of malaria, although their mechanism of action remains uncertain. Primaquine has traditionally been used to treat the dormant hypnozoite stage of <italic>P. vivax</italic> and it is also effective against <italic>P. falciparum</italic> gametocytes. The main deficiency of this compound is its toxicity in patients with G6PD deficiency. A number of 8-aminoquinoline derivatives, such as tafenoquine, lack some of the undesirable effects of primaquine and are also being advanced for preventing relapse of <italic>P. vivax</italic> (<xref ref-type="bibr" rid="c74">74</xref>). Unfortunately, the 8-aminoquinolines as a class were largely inactive against <italic>T. gondii</italic> tachyzoites (<xref ref-type="table" rid="tbl1">Table 1</xref>). However, given their differential activity on semi-dormant stages of <italic>Plasmodium</italic> development (i.e. gametocytes and hypnozoites) it would be interesting to test these compounds on bradyzoites of <italic>T. gondii</italic>.</p>
<p>Artemisinin derivatives have become the mainstay of combined therapy against severe and uncomplicated malaria (<xref ref-type="bibr" rid="c31">31</xref>). Artemsinin is potent across the stages of intraerythrocytic development and this activity has been attributed to hemoglobin degradation and release of free heme, which is thought to activate the endoperoxide bridge, likely forming adducts with multiple targets (<xref ref-type="bibr" rid="c33">33</xref>). More recent efforts have focused on completely synthetic endoperoxides, some of which show greater metabolic stability in vivo, and which could reduce reliance on the natural product produced from <italic>Artemesia</italic> cultivation (<xref ref-type="bibr" rid="c75">75</xref>). Consistent with prior studies (<xref ref-type="bibr" rid="c35">35</xref>, <xref ref-type="bibr" rid="c37">37</xref>), a number of artemisinin derivatives were modestly active in inhibiting <italic>T. gondii</italic> growth (<xref ref-type="table" rid="tbl1">Table 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>). Artemisone and artemether were among the most active derivatives, while deoxyartemesinin was inactive, indicating that activity is dependent on the endoperoxide moiety. Unfortunately, more stable trioxolane synthetic peroxides such as OZ439 and OZ277 were much less active on <italic>T. gondii</italic> (<xref ref-type="table" rid="tbl1">Table 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>). Even the most potent artemisinin derivatives are several orders of magnitude less effective against <italic>T. gondii</italic> compared to <italic>P. falciparum</italic>, thus limiting their potential as therapeutic options for toxoplasmosis.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2</label>
<caption>
<p>Structures and EC<sub>50</sub> values for artemesinin and related analogs artusunate and artemether. Deoxyartemesinin, which is inactive, is shown for comparison. Several synthetic trioxanes are also illustrated. See <xref ref-type="table" rid="tbl1">Table 1</xref> for complete EC<sub>50</sub> values.</p>
</caption>
<graphic xlink:href="316455_fig2.tif"/>
</fig>
<p>Several different chemical scaffolds have been shown to inhibit the P-type cation translocating ATPase in <italic>P. falciparum</italic> known as PfATP4, which resides in the parasite plasma membrane where it modulates cytosolic sodium levels by active extrusion of Na<sup>&#x002B;</sup> in exchange for H<sup>&#x002B;</sup> (<xref ref-type="bibr" rid="c76">76</xref>). Among the most potent PfATP4 inhibitors are the spiroindolones that are currently in clinical trials for treatment of infection by <italic>P. falciparum</italic> (<xref ref-type="bibr" rid="c50">50</xref>). The spiroindolone KAE609 (also known as NITD609), which is highly active on <italic>P. falciparum</italic> (<xref ref-type="bibr" rid="c41">41</xref>-<xref ref-type="bibr" rid="c43">43</xref>), was among the more active molecules studied here for inhibition of <italic>T. gondii</italic> growth (EC<sub>50</sub> &#x007E; 0.25 &#x03BC;M) (<xref ref-type="table" rid="tbl1">Table 1</xref>, <xref ref-type="fig" rid="fig3">Figure 3</xref>). KAE609 was substantially more potent than a second spiroindolone analog KAF246 (EC<sub>50</sub> &#x003D; 1.4 &#x03BC;M) (<xref ref-type="table" rid="tbl1">Table 1</xref>, <xref ref-type="fig" rid="fig3">Figure 3</xref>), although these two compounds differ only by substitution of Cl for F on the indole group (<xref ref-type="fig" rid="fig3">Figure 3</xref>). KAE609 was previously reported to inhibit <italic>T. gondii</italic> growth in vitro with a 50&#x0025; decrease in parasite growth at 1 &#x03BC;M (reported as MIC<sub>50</sub>) and in a mouse model for acute toxoplasmosis when the compound was administered at 100 mg/kg (given orally on the day of infection and the day after infection) (<xref ref-type="bibr" rid="c77">77</xref>). Compound 21A092, which belongs to a different scaffold known as a pyrazoleamide, also targets PfATP4 and is highly active on <italic>P. falciparum</italic> (<xref ref-type="bibr" rid="c78">78</xref>), but was much less potent on <italic>T. gondii</italic> (<xref ref-type="table" rid="tbl1">Table 1</xref>). Unfortunately, even potent spiroindoles like KAE609 show much greater potency on <italic>P. falciparum</italic> (EC<sub>50</sub> &#x007E;1 nM) (<xref ref-type="bibr" rid="c42">42</xref>) than <italic>T. gondii</italic>, despite the fact that the proposed binding site in PfATP4 is highly conserved, including sites that result in resistance when mutated (<xref ref-type="bibr" rid="c77">77</xref>). Interestingly, the relative potency between the ATP4 inhibitors (highest to lowest) KAE609, PA92 and SJ733 on <italic>P. falciparum</italic> appears to match that in <italic>T. gondii</italic>. A number of other chemical scaffolds have also been shown to affect PfATP4 in <italic>P. falciparum</italic> and a previous screen of the Malaria Box identified a number of compounds that likely target PfATP4 (<xref ref-type="bibr" rid="c76">76</xref>) as inhibitors of <italic>T. gondii</italic> (<xref ref-type="bibr" rid="c48">48</xref>). As many analogs of the spiroindolones, and other scaffolds that act on PfATP4, are available, it may be worth further investigation of this target to identify more potent inhibitors of <italic>T. gondii</italic>.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3</label>
<caption>
<p>Structures and EC<sub>50</sub> values for several PfATP4 inhibitors including two spiroindolones (KAE609 and KAF246) and a structurally unrelated pyrazoleamide (21A092). See <xref ref-type="table" rid="tbl1">Table 1</xref> for complete EC<sub>50</sub> values.</p>
</caption>
<graphic xlink:href="316455_fig3.tif"/>
</fig>
<p>Additionally, potent new antimalarial compounds that have been recently identified showed only modest activity against <italic>T. gondii</italic> with EC<sub>50</sub> values that ranged from 1 &#x2013; 5 &#x03BC;M (<xref ref-type="table" rid="tbl1">Table 1</xref>). Included in this group was KAF156, an imidazolopiperazine that showed promising results in a recent clinical trial of <italic>P. falciparum</italic> malaria (<xref ref-type="bibr" rid="c79">79</xref>). Additionally, several inhibitors of phosphoinositol 4 kinase (PI4K) showed modest (i.e. UTC944), or no appreciable (i.e. KDU691), activity against <italic>T. gondii</italic> growth, despite having excellent potency against <italic>P. falciparum</italic> (<xref ref-type="bibr" rid="c80">80</xref>). Similarly, cladosporin, which targets lysyl tRNA synthase in <italic>P. falciparum</italic> (<xref ref-type="bibr" rid="c81">81</xref>, <xref ref-type="bibr" rid="c82">82</xref>), showed only modest activity against <italic>T. gondii</italic> (<xref ref-type="table" rid="tbl1">Table 1</xref>). The reasons for the much lower activities observed on <italic>T. gondii</italic> is uncertain but it may reflect differences in the molecular targets of these compounds or differences in the extent with which these targets play essential roles in the biology of <italic>T. gondii</italic> vs. <italic>P. falciparum</italic>. Alternatively, these differences might arise from differences in the intracellular compartment that affect access of the compounds or from a greater number of efflux mechanisms in <italic>T. gondii</italic>. Regardless of the precise reasons, these differences in sensitivity provide a rationale to explore a more diverse collection of compounds than studied here, with the potential that other analogs within these chemical scaffolds will be found to be more effective on <italic>T. gondii</italic>.</p>
<p>Targeting conserved and essential pathways may thus offer greater advantage for finding compounds with a broader spectrum of activity. One potential example is pyrimidine biosynthesis that is conserved in both <italic>T. gondii</italic> and <italic>P. falciparum</italic>. In particular, <italic>Plasmodium</italic> lacks pyrimidine salvage enzymes and thus is reliant on biosynthesis for RNA and DNA synthesis. Targeted screens have advanced new triazolopyrimidine compounds as inhibitors of <italic>P. falciparum</italic> dihydroorotate dehydrogenase (DHODH), thus blocking pyrimidine biosynthesis (<xref ref-type="bibr" rid="c83">83</xref>). One such analog DSM265 is active against both liver and blood stages of <italic>P. falciparum</italic>, shows excellent pharmacokinetic and safety properties, and has advanced to clinical trials for <italic>P. falciparum</italic> malaria (<xref ref-type="bibr" rid="c84">84</xref>). DHODH is also essential in for pyrimidine biosynthesis in <italic>T. gondii</italic>, as well as performing another essential function in mitochondria (<xref ref-type="bibr" rid="c85">85</xref>). However, DSM265 was not effective at inhibiting <italic>T. gondii</italic> growth in vitro (<xref ref-type="table" rid="tbl1">Table 1</xref>). This difference may reflect that fact that DSM265 has been carefully selected for potency on <italic>P. falciparum</italic> hence this may reflect a difference in the molecular target, suggesting that other analogs may be more effective. Alternatively this result that may be due to the capacity of <italic>T. gondii</italic> to salvage uracil (<xref ref-type="bibr" rid="c86">86</xref>). Hence, even apparently conserved pathways present challenges for identification of potent inhibitors both due to potential molecular differences in the target and/or alternative metabolic routes in these two parasites.</p>
</sec>
<sec id="s3">
<title>Conclusions</title>
<p>We evaluated 80 compounds that are used as current therapy for malaria, or which are in late stage development, for their ability to inhibit the growth of the related apicomplexan parasite <italic>T. gondii</italic>. The most active compounds identified were previously known agents including lincosamide and macrolide antibiotics that target the apicoplast and quinolones that target the bc1 complex in the mitochondria. Consistent with this pattern, artemisinin and related analogs, were modestly potent, while several new generation trioxanes showed very little activity. Moreover, traditional drugs used against malaria including 4-amino and 8-aminoquinolines showed very little activity against <italic>T. gondii</italic>. Similarly, a number of newly identified compound classes that target novel pathways in <italic>Plasmodium</italic> showed limited activity against <italic>T. gondii</italic> including spiroindolones, which inhibit PfATP4, as well as compounds that target PI4K, lysyl tRNA synthase, and others. These findings may suggest that current malaria drugs target pathways that are not conserved in these two parasites, or alternatively that differences in the molecular target will require different analogs to effectively target each of these parasites. Hence, identifying new treatments for toxoplasmosis will require a concerted effort to identify potent inhibitors of essential targets in this organism.</p>
</sec>
<sec id="s4">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Cell culture and parasite propagation</title>
<p>Tachyzoites of ME49 strain encoding a transgenic copy of firefly luciferase (type II, ME49-FLuc) (<xref ref-type="bibr" rid="c87">87</xref>) were continually passaged in confluent monolayers of human foreskin fibroblasts (HFF) cultured in DMEM supplemented with 10&#x0025; fetal bovine serum (FBS), glutamine (10 mM) and gentamycin (10 &#x03BC;g/mL). To isolate parasites, heavily infected cultures of late-stage vacuoles containing replicating tachyzoites were scraped, force lysed through a 23g needle and residual host cell material removed using a polycarbonate filter (3 micron pore). The parasites were then counted, diluted in fresh culture medium and added to 96-well plates as described below. All HFF and parasite cultures were grown in a 37&#x00B0;C incubator supplemented with 5&#x0025; CO<sub>2</sub> and were verified to be mycoplasma free using the e-Myco Plus kit (Intron Biotechnology).</p>
</sec>
<sec id="s4b">
<title>Luciferase based growth inhibition assays</title>
<p>HFF cells were plated in white, clear-bottom 96-well plates (Costar &#x0023;3610) and incubated to confluency. Only the inner 60 wells were used to reduce variability due to edge affect with outside wells. Compounds KAF246 and KDU691 were obtained from Novartis Tropical Research Institute. The remaining compounds were provided by MMV. All compounds were prepared as 10 mM stock in 100&#x0025; DMSO and stored at -80&#x00B0;C until use. After dilution, the final DMSO concentration for all experimental wells was 0.1&#x0025;. Pyrimethamine (Sigma-Aldrich, &#x0023;46706) was reconstituted in 100&#x0025; DMSO at 5 mM stock concentration and stored at -20&#x00B0;C until use.</p>
<p>For the single point assay, 5x10<sup>3</sup> ME49-FLuc parasites (in 100 &#x03BC;L volume) were inoculated into plates containing 100 &#x03BC;L of 2x compound (10 &#x03BC;M final concentration, 200 &#x03BC;L final well volume), incubated for 72h at 37&#x00B0;C and luciferase activity evaluated using the Luciferase Assay System (Promega, E1501) according manufacturers protocol. Briefly, culture medium was aspirated and replaced with 40 &#x03BC;L of 1x Passive Lysis buffer (1xPLB, Promega, E1531) and incubated for 5 min at room temperature (RT). Luciferase activity was measured on a Beckman Coulter integrated and automated platform using the following protocol: Inject 100 &#x03BC;L of Luciferase Assay Reagent (LAR), shake 1 sec and read 10 sec post-injection. Only compounds that showed greater than 50&#x0025; growth inhibition over DMSO control were selected for EC<sub>50</sub> determination (average of 3 biological replicates). Liquid handling steps (media exchange, compound dilution and addition and luciferase assay steps) were performed on a Biomek Dual Pod FX system using the SAMI EX software as part of the High Throughput Screening Center at Washington University School of Medicine.</p>
<p>For compounds demonstrated &#x003E;50&#x0025; growth inhibition at 10 &#x03BC;M, EC<sub>50</sub> values were determined form a 10-point dose-response curve. Briefly, 5x10&#x005E;3 ME49-FLuc parasites (100 &#x03BC;L/well) were added to a 96-well plate that contained 100 uL of 2x compound (1x final compound concentration, 200 &#x03BC;L total well volume,) and allowed to replicate for 72h prior to preparation for luciferase assay. All experimental steps, growth conditions and luciferase assay protocols were completed as described above. Compounds were tested using a 3-fold dilution series from 10 &#x03BC;M to 0.001 &#x03BC;M with all wells containing a final concentration of 0.1&#x0025; DMSO. Pyrimethamine (2.5 &#x03BC;M, positive control) and DMSO (vehicle) controls were added to the outside wells of all plates as controls. The EC<sub>50</sub> data are presented as the average of two biological replicates.</p>
</sec>
<sec id="s4c">
<title>Statistics</title>
<p>All results are presented as the average of two or more biological replicates. Linear regression analysis and dose-response inhibition (Log (inhibitor) vs. normalized response &#x2013; variable slope) or (Log (inhibitor) vs. normalized response) were performed in Prism 7 (GraphPad Software, Inc.).</p>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgement</title>
<p>We thank Dr. Thierry Diagana, Novartis Institute for Tropical Diseases, for providing KAF246 (aka NITD246) and KDU691, Jennifer Barks for assistance with cell culture, and Dr. Maxine Ilagan, High-Throughput Screening Center at Washington University School of Medicine, for assistance with compound screening. Supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U19AI109725.</p>
</ack>
<sec>
<title>Ancillary Information</title>
<sec>
<title>Supporting Information</title>
</sec>
<sec>
<title>Author contributions</title>
<p>JBR designed or performed screening assays; JBR and LDS analyzed primary screening data and generated figures; JB and DEG reviewed the findings and provided scientific advice; JBR and LDS wrote the manuscript with input from all authors.</p>
</sec>
</sec>
<glossary>
<title>Abbreviations used</title>
<def-list>
<def-item>
<term>ART</term>
<def><p>artemisinin</p></def>
</def-item>
<def-item>
<term>DHFR</term>
<def><p>dihydrofolate reductase</p></def>
</def-item>
<def-item>
<term>DHODH</term>
<def><p>dihydroorotate dehydrogenase</p></def>
</def-item>
<def-item>
<term>PfATP4</term>
<def><p>adenosine triphophosphatase 4</p></def>
</def-item>
<def-item>
<term>HFF</term>
<def><p>human foreskin fibroblasts</p></def>
</def-item>
<def-item>
<term>HTS</term>
<def><p>high throughput screen</p></def>
</def-item>
<def-item>
<term>PI4K</term>
<def><p>phosphotidylinositol 4 phosphate kinase</p></def>
</def-item>
<def-item>
<term>EC</term>
<def><p>effective concentration</p></def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Lorenzi</surname> <given-names>H</given-names></string-name>, <string-name><surname>Khan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Behnke</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Namasivayam</surname> <given-names>S</given-names></string-name>, <string-name><surname>Swapna</surname> <given-names>LS</given-names></string-name>, <string-name><surname>Hadjithomas</surname> <given-names>M</given-names></string-name>, <string-name><surname>Karamycheva</surname> <given-names>S</given-names></string-name>, <string-name><surname>Pinney</surname> <given-names>D</given-names></string-name>, <string-name><surname>Brunk</surname> <given-names>BP</given-names></string-name>, <string-name><surname>Ajioka</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Ajzenberg</surname> <given-names>D</given-names></string-name>, <string-name><surname>Boothroyd</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Boyle</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Darde</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Diaz-Miranda</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Dubey</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Fritz</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Gennari</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Gregory</surname> <given-names>BD</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>K</given-names></string-name>, <string-name><surname>Saeij</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Su</surname> <given-names>C</given-names></string-name>, <string-name><surname>White</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>XQ</given-names></string-name>, <string-name><surname>Howe</surname> <given-names>DK</given-names></string-name>, <string-name><surname>Rosenthal</surname> <given-names>BM</given-names></string-name>, <string-name><surname>Grigg</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Parkinson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kissinger</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Roos</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Sibley</surname> <given-names>LD</given-names></string-name>. <article-title>Local admixture of amplified and diversified secreted pathogenesis determinants shapes mosaic Toxoplasma gondii genomes</article-title>. <source>Nature communications</source>. <year>2016</year>;<volume>7</volume>:<fpage>10147</fpage>. PMID: <pub-id pub-id-type="pmid">26738725</pub-id>; <pub-id pub-id-type="pmid">4729833</pub-id>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Dubey</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>NL</given-names></string-name>, <string-name><surname>Frenkel</surname> <given-names>JK</given-names></string-name>. <article-title>The <italic>Toxoplasma gondii</italic> oocyst from cat feces</article-title>. <source>Journal of Experimental Medicine</source>. <year>1970</year>;<volume>132</volume>(<issue>4</issue>):<fpage>636</fpage>&#x2013;<lpage>662</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Frenkel</surname> <given-names>JK</given-names></string-name>, <string-name><surname>Dubey</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>NL</given-names></string-name>. <article-title><italic>Toxoplasma gondii</italic>: fecal forms separated from eggs of the nematode toxocara cati</article-title>. <source>Science</source>. <year>1969</year>;<volume>164</volume>:<fpage>432</fpage>&#x2013;<lpage>433</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Dubey</surname> <given-names>JP</given-names></string-name>. <article-title>Bradyzoite-induced murine toxoplasmosis: stage conversion pathogenesis, and tissue cyst formation in mice fed bradyzoites of different strains of <italic>Toxoplasma gondii</italic></article-title>. <source>J Euk Microb</source>. <year>1997</year>;<volume>44</volume>(<issue>6</issue>):<fpage>592</fpage>&#x2013;<lpage>602</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Dubey</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Frenkel</surname> <given-names>JK</given-names></string-name>. <article-title>Experimental <italic>toxoplasma</italic> infection in mice with strains producing oocysts</article-title>. <source>Journal of Parasitology</source>. <year>1973</year>;<volume>59</volume>(<issue>3</issue>):<fpage>505</fpage>&#x2013;<lpage>512</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Dubey</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Speer</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Kwok</surname> <given-names>OCH</given-names></string-name>, <string-name><surname>Blixt</surname> <given-names>JA</given-names></string-name>. <article-title>Oocyst-induced murine Toxoplasmosis: life cycle, pathogenicity, and stage conversion in mice fed <italic>Toxoplasma gondii</italic> oocysts</article-title>. <source>Journal of Parasitology</source>. <year>1997</year>;<volume>83</volume>:<fpage>870</fpage>&#x2013;<lpage>882</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Pappas</surname> <given-names>G</given-names></string-name>, <string-name><surname>Roussos</surname> <given-names>N</given-names></string-name>, <string-name><surname>Falagas</surname> <given-names>ME</given-names></string-name>. <article-title>Toxoplasmosis snapshots: global status of <italic>Toxoplasma gondii</italic> seroprevalence and implications for pregnancy and congenital toxoplasmosis</article-title>. <source>Int J Parasitol</source>. <year>2009</year>;<volume>39</volume>(<issue>12</issue>):<fpage>1385</fpage>&#x2013;<lpage>1394</lpage>. PMID: <pub-id pub-id-type="pmid">19433092</pub-id>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Jones</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Dubey</surname> <given-names>JP</given-names></string-name>. <article-title>Waterborne toxoplasmosis--recent developments</article-title>. <source>Exp Parasitol</source>. <year>2010</year>;<volume>124</volume>(<issue>1</issue>):<fpage>10</fpage>&#x2013;<lpage>25</lpage>. PMID: <pub-id pub-id-type="pmid">19324041</pub-id>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Torgerson</surname> <given-names>PR</given-names></string-name>, <string-name><surname>Mastroiacovo</surname> <given-names>P</given-names></string-name>. <article-title>The global burden of congenital toxoplasmosis: a systematic review</article-title>. <source>Bull World Health Organ</source>. <year>2013</year>;<volume>91</volume>(<issue>7</issue>):<fpage>501</fpage>&#x2013;<lpage>508</lpage>. PMID: <pub-id pub-id-type="pmid">23825877</pub-id>; <pub-id pub-id-type="pmid">3699792</pub-id>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Luft</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Remington</surname> <given-names>JS</given-names></string-name>. <article-title>Toxoplasmic encephalitis in AIDS</article-title>. <source>Clin Infect Dis</source>. <year>1992</year>;<volume>15</volume>:<fpage>211</fpage>&#x2013;<lpage>222</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Israelski</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Remington</surname> <given-names>JS</given-names></string-name>. <article-title>Toxoplasmosis in the non-AIDS immunocompromised host</article-title>. <source>Curr Clin Top Infect Dis</source>. <year>1993</year>;<volume>13</volume>:<fpage>322</fpage>&#x2013;<lpage>356</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Pfaff</surname> <given-names>AW</given-names></string-name>, <string-name><surname>de-la-Torre</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rochet</surname> <given-names>E</given-names></string-name>, <string-name><surname>Brunet</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sabou</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sauer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bourcier</surname> <given-names>T</given-names></string-name>, <string-name><surname>Gomez-Marin</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Candolfi</surname> <given-names>E</given-names></string-name>. <article-title>New clinical and experimental insights into Old World and neotropical ocular toxoplasmosis</article-title>. <source>Int J Parasitol</source>. <year>2013</year>. PMID: <pub-id pub-id-type="pmid">24200675</pub-id>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Demar</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hommel</surname> <given-names>D</given-names></string-name>, <string-name><surname>Djossou</surname> <given-names>F</given-names></string-name>, <string-name><surname>Peneau</surname> <given-names>C</given-names></string-name>, <string-name><surname>Boukhari</surname> <given-names>R</given-names></string-name>, <string-name><surname>Louvel</surname> <given-names>D</given-names></string-name>, <string-name><surname>Bourbigot</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Nasser</surname> <given-names>V</given-names></string-name>, <string-name><surname>Ajzenberg</surname> <given-names>D</given-names></string-name>, <string-name><surname>Darde</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Carme</surname> <given-names>B</given-names></string-name>. <article-title>Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana</article-title>. <source>Clin Microbiol Infect</source>. <year>2012</year>;<volume>18</volume>(<issue>7</issue>):<fpage>E221</fpage>&#x2013;<lpage>231</lpage>. PMID: <pub-id pub-id-type="pmid">21958195</pub-id>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Pawlowski</surname> <given-names>J</given-names></string-name>, <string-name><surname>Audic</surname> <given-names>S</given-names></string-name>, <string-name><surname>Adl</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bass</surname> <given-names>D</given-names></string-name>, <string-name><surname>Belbahri</surname> <given-names>L</given-names></string-name>, <string-name><surname>Berney</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bowser</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Cepicka</surname> <given-names>I</given-names></string-name>, <string-name><surname>Decelle</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dunthorn</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fiore-Donno</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Gile</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Holzmann</surname> <given-names>M</given-names></string-name>, <string-name><surname>Jahn</surname> <given-names>R</given-names></string-name>, <string-name><surname>Jirku</surname> <given-names>M</given-names></string-name>, <string-name><surname>Keeling</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Kostka</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kudryavtsev</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lara</surname> <given-names>E</given-names></string-name>, <string-name><surname>Lukes</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mann</surname> <given-names>DG</given-names></string-name>, <string-name><surname>Mitchell</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Nitsche</surname> <given-names>F</given-names></string-name>, <string-name><surname>Romeralo</surname> <given-names>M</given-names></string-name>, <string-name><surname>Saunders</surname> <given-names>GW</given-names></string-name>, <string-name><surname>Simpson</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Smirnov</surname> <given-names>AV</given-names></string-name>, <string-name><surname>Spouge</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Stern</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Stoeck</surname> <given-names>T</given-names></string-name>, <string-name><surname>Zimmermann</surname> <given-names>J</given-names></string-name>, <string-name><surname>Schindel</surname> <given-names>D</given-names></string-name>, <string-name><surname>de Vargas</surname> <given-names>C</given-names></string-name>. <article-title>CBOL protist working group: barcoding eukaryotic richness beyond the animal, plant, and fungal kingdoms</article-title>. <source>PLoS biology</source>. <year>2012</year>;<volume>10</volume>(<issue>11</issue>):<fpage>e1001419</fpage>. PMID: <pub-id pub-id-type="pmid">23139639</pub-id>; <pub-id pub-id-type="pmid">3491025</pub-id>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Miller</surname> <given-names>LH</given-names></string-name>, <string-name><surname>Ackerman</surname> <given-names>HC</given-names></string-name>, <string-name><surname>Su</surname> <given-names>XZ</given-names></string-name>, <string-name><surname>Wellems</surname> <given-names>TE</given-names></string-name>. <article-title>Malaria biology and disease pathogenesis: insights for new treatments</article-title>. <source>Nat Med</source>. <year>2013</year>;<volume>19</volume>(<issue>2</issue>):<fpage>156</fpage>&#x2013;<lpage>167</lpage>. PMID: <pub-id pub-id-type="pmid">23389616</pub-id>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Kotloff</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Nataro</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Blackwelder</surname> <given-names>WC</given-names></string-name>, <string-name><surname>Nasrin</surname> <given-names>D</given-names></string-name>, <string-name><surname>Farag</surname> <given-names>TH</given-names></string-name>, <string-name><surname>Panchalingam</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Sow</surname> <given-names>SO</given-names></string-name>, <string-name><surname>Sur</surname> <given-names>D</given-names></string-name>, <string-name><surname>Breiman</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Faruque</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Zaidi</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Saha</surname> <given-names>D</given-names></string-name>, <string-name><surname>Alonso</surname> <given-names>PL</given-names></string-name>, <string-name><surname>Tamboura</surname> <given-names>B</given-names></string-name>, <string-name><surname>Sanogo</surname> <given-names>D</given-names></string-name>, <string-name><surname>Onwuchekwa</surname> <given-names>U</given-names></string-name>, <string-name><surname>Manna</surname> <given-names>B</given-names></string-name>, <string-name><surname>Ramamurthy</surname> <given-names>T</given-names></string-name>, <string-name><surname>Kanungo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ochieng</surname> <given-names>JB</given-names></string-name>, <string-name><surname>Omore</surname> <given-names>R</given-names></string-name>, <string-name><surname>Oundo</surname> <given-names>JO</given-names></string-name>, <string-name><surname>Hossain</surname> <given-names>A</given-names></string-name>, <string-name><surname>Das</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Ahmed</surname> <given-names>S</given-names></string-name>, <string-name><surname>Qureshi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Quadri</surname> <given-names>F</given-names></string-name>, <string-name><surname>Adegbola</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Antonio</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hossain</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Akinsola</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mandomando</surname> <given-names>I</given-names></string-name>, <string-name><surname>Nhampossa</surname> <given-names>T</given-names></string-name>, <string-name><surname>Acacio</surname> <given-names>S</given-names></string-name>, <string-name><surname>Biswas</surname> <given-names>K</given-names></string-name>, <string-name><surname>O&#x2019;Reilly</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Mintz</surname> <given-names>ED</given-names></string-name>, <string-name><surname>Berkeley</surname> <given-names>LY</given-names></string-name>, <string-name><surname>Muhsen</surname> <given-names>K</given-names></string-name>, <string-name><surname>Sommerfelt</surname> <given-names>H</given-names></string-name>, <string-name><surname>Robins-Browne</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Levine</surname> <given-names>MM</given-names></string-name>. <article-title>Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study</article-title>. <source>Lancet</source>. <year>2013</year>;<volume>382</volume>(<issue>9888</issue>):<fpage>209</fpage>&#x2013;<lpage>222</lpage>. PMID: <pub-id pub-id-type="pmid">23680352</pub-id>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Templeton</surname> <given-names>TJ</given-names></string-name>, <string-name><surname>Iyer</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Anantharaman</surname> <given-names>V</given-names></string-name>, <string-name><surname>Enomoto</surname> <given-names>S</given-names></string-name>, <string-name><surname>Abrahante</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Subramanian</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Hoffman</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Abrahamsen</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Aravind</surname> <given-names>L</given-names></string-name>. <article-title>Comparative analysis of apicomplexa and genomic diversity in eukaryotes</article-title>. <source>Gen Res</source>. <year>2004</year>;<volume>14</volume>:<fpage>1686</fpage>&#x2013;<lpage>1695</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Berney</surname> <given-names>C</given-names></string-name>, <string-name><surname>Pawlowski</surname> <given-names>J</given-names></string-name>. <article-title>A molecular time-scale for eukaryote evolution recalibrated with the continuous microfossil record</article-title>. <source>Proc Biol Sci</source>. <year>2006</year>;<volume>273</volume>(<issue>1596</issue>):<fpage>1867</fpage>&#x2013;<lpage>1872</lpage>. PMID: <pub-id pub-id-type="pmid">16822745</pub-id>; <pub-id pub-id-type="doi">1634798</pub-id>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname> <given-names>L</given-names></string-name>, <string-name><surname>Stoeckert</surname> <given-names>CJ</given-names>, <suffix>Jr.</suffix></string-name>, <string-name><surname>Roos</surname> <given-names>DS</given-names></string-name>. <article-title>OrthoMCL: identification of ortholog groups for eukaryotic genomes</article-title>. <source>Genome Res</source>. <year>2003</year>;<volume>13</volume>(<issue>9</issue>):<fpage>2178</fpage>&#x2013;<lpage>2189</lpage>. PMID: <pub-id pub-id-type="pmid">12952885</pub-id>; <pub-id pub-id-type="doi">403725</pub-id>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Hyde</surname> <given-names>JE</given-names></string-name>. <article-title>Targeting purine and pyrimidine metabolism in human apicomplexan parasites</article-title>. <source>Curr Drug Targets</source>. <year>2007</year>;<volume>8</volume>(<issue>1</issue>):<fpage>31</fpage>&#x2013;<lpage>47</lpage>. PMID: <pub-id pub-id-type="pmid">17266529</pub-id>; <pub-id pub-id-type="pmcid">PMC2720675</pub-id>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Neville</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Zach</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Larson</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Judge</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Davis</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Vennerstrom</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Davis</surname> <given-names>PH</given-names></string-name>. <article-title>Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>(<issue>12</issue>):<fpage>7161</fpage>&#x2013;<lpage>7169</lpage>. PMID: <pub-id pub-id-type="pmid">26392504</pub-id>; <pub-id pub-id-type="pmcid">PMC4649158</pub-id>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Wei</surname> <given-names>HX</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Lindsay</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>HJ</given-names></string-name>. <article-title>A Systematic Review and Meta-Analysis of the Efficacy of Anti-Toxoplasma gondii Medicines in Humans</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>9</issue>):<fpage>e0138204</fpage>. PMID: <pub-id pub-id-type="pmid">26394212</pub-id>; <pub-id pub-id-type="pmcid">PMC4578932</pub-id>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="book"><string-name><surname>McCabe</surname> <given-names>RE</given-names></string-name>. <chapter-title>Antitoxoplasma chemotherapy</chapter-title>. In: <person-group person-group-type="editor"><string-name><surname>Joynson</surname> <given-names>DHM</given-names></string-name>, <string-name><surname>Wreghitt</surname> <given-names>TG</given-names></string-name></person-group>, editors. <source>Toxoplasmosis: a comprehensive clinical guide</source>. <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Cambridge Univ. Press</publisher-name>; <year>2001</year>. p. <fpage>319</fpage>&#x2013;<lpage>359</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Ben-Harari</surname> <given-names>RR</given-names></string-name>, <string-name><surname>Goodwin</surname> <given-names>E</given-names></string-name>, <string-name><surname>Casoy</surname> <given-names>J</given-names></string-name>. <article-title>Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review</article-title>. <source>Drugs R D</source>. <year>2017</year>;<volume>17</volume>(<issue>4</issue>):<fpage>523</fpage>&#x2013;<lpage>544</lpage>. PMID: <pub-id pub-id-type="pmid">28879584</pub-id>; <pub-id pub-id-type="pmcid">PMC5694419</pub-id>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Hernandez</surname> <given-names>AV</given-names></string-name>, <string-name><surname>Thota</surname> <given-names>P</given-names></string-name>, <string-name><surname>Pellegrino</surname> <given-names>D</given-names></string-name>, <string-name><surname>Pasupuleti</surname> <given-names>V</given-names></string-name>, <string-name><surname>Benites-Zapata</surname> <given-names>VA</given-names></string-name>, <string-name><surname>Deshpande</surname> <given-names>A</given-names></string-name>, <string-name><surname>Penalva de Oliveira</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Vidal</surname> <given-names>JE</given-names></string-name>. <article-title>A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option&#x003F;</article-title> <source>HIV Med</source>. <year>2017</year>;<volume>18</volume>(<issue>2</issue>):<fpage>115</fpage>&#x2013;<lpage>124</lpage>. PMID: <pub-id pub-id-type="pmid">27353303</pub-id>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Kieffer</surname> <given-names>F</given-names></string-name>, <string-name><surname>Wallon</surname> <given-names>M</given-names></string-name>. <article-title>Congenital toxoplasmosis</article-title>. <source>Handb Clin Neurol</source>. <year>2013</year>;<volume>112</volume>:<fpage>1099</fpage>&#x2013;<lpage>1101</lpage>. PMID: <pub-id pub-id-type="pmid">23622316</pub-id>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Adeyemi</surname> <given-names>OS</given-names></string-name>, <string-name><surname>Sugi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Han</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Kato</surname> <given-names>K</given-names></string-name>. <article-title>Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents</article-title>. <source>Parasitol Res</source>. <year>2018</year>;<volume>117</volume>(<issue>2</issue>):<fpage>355</fpage>&#x2013;<lpage>363</lpage>. PMID: <pub-id pub-id-type="pmid">29260298</pub-id>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Benmerzouga</surname> <given-names>I</given-names></string-name>, <string-name><surname>Checkley</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Ferdig</surname> <given-names>MT</given-names></string-name>, <string-name><surname>Arrizabalaga</surname> <given-names>G</given-names></string-name>, <string-name><surname>Wek</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Sullivan</surname> <given-names>WJ</given-names>, <suffix>Jr.</suffix></string-name> <article-title>Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>(<issue>11</issue>):<fpage>6939</fpage>&#x2013;<lpage>6945</lpage>. PMID: <pub-id pub-id-type="pmid">26303803</pub-id>; <pub-id pub-id-type="pmcid">PMC4604420</pub-id>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Konrad</surname> <given-names>C</given-names></string-name>, <string-name><surname>Queener</surname> <given-names>SF</given-names></string-name>, <string-name><surname>Wek</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Sullivan</surname> <given-names>WJ</given-names>, <suffix>Jr.</suffix></string-name> <article-title>Inhibitors of eIF2alpha dephosphorylation slow replication and stabilize latency in Toxoplasma gondii</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2013</year>;<volume>57</volume>(<issue>4</issue>):<fpage>1815</fpage>&#x2013;<lpage>1822</lpage>. PMID: <pub-id pub-id-type="pmid">23380722</pub-id>; <pub-id pub-id-type="pmcid">PMC3623309</pub-id>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Dittmar</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Drozda</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Blader</surname> <given-names>IJ</given-names></string-name>. <article-title>Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma gondii Growth</article-title>. <source>mSphere</source>. <year>2016</year>;<volume>1</volume>(<issue>2</issue>). PMID: <pub-id pub-id-type="pmid">27303726</pub-id>; <pub-id pub-id-type="pmcid">PMC4894684</pub-id>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Eastman</surname> <given-names>RT</given-names></string-name>, <string-name><surname>Fidock</surname> <given-names>DA</given-names></string-name>. <article-title>Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria</article-title>. <source>Nat Rev Microbiol</source>. <year>2009</year>;<volume>7</volume>(<issue>12</issue>):<fpage>864</fpage>&#x2013;<lpage>874</lpage>. PMID: <pub-id pub-id-type="pmid">19881520</pub-id>; <pub-id pub-id-type="pmcid">PMC2901398</pub-id>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Wellems</surname> <given-names>TE</given-names></string-name>, <string-name><surname>Plowe</surname> <given-names>CV</given-names></string-name>. <article-title>Chloroquine-resistant malaria</article-title>. <source>Journal of Infectious Diseases</source>. <year>2001</year>;<volume>184</volume>:<fpage>770</fpage>&#x2013;<lpage>776</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>O&#x2019;Neill</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Barton</surname> <given-names>VE</given-names></string-name>, <string-name><surname>Ward</surname> <given-names>SA</given-names></string-name>. <article-title>The molecular mechanism of action of artemisinin--the debate continues</article-title>. <source>Molecules</source>. <year>2010</year>;<volume>15</volume>(<issue>3</issue>):<fpage>1705</fpage>&#x2013;<lpage>1721</lpage>. PMID: <pub-id pub-id-type="pmid">20336009</pub-id>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Jones-Brando</surname> <given-names>L</given-names></string-name>, <string-name><surname>D&#x2019;Angelo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Posner</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Yolken</surname> <given-names>RH</given-names></string-name>. <article-title><italic>In vitro</italic> inhibition of <italic>Toxoplasma gondii</italic> by four new derivatives of artemisinin</article-title>. <source>Antimicrob Agents Chem</source>. <year>2006</year>;<volume>50</volume>:<fpage>4206</fpage>&#x2013;<lpage>4208</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Nagamune</surname> <given-names>K</given-names></string-name>, <string-name><surname>Moreno</surname> <given-names>SNJ</given-names></string-name>, <string-name><surname>Sibley</surname> <given-names>LD</given-names></string-name>. <article-title>Artemisinin resistant mutants of <italic>Toxoplasma gondii</italic> have altered calcium homeostasis</article-title>. <source>Anti Microb Agents Chemother</source>. <year>2007</year>;<volume>51</volume>:<fpage>3816</fpage>&#x2013;<lpage>3823</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Hencken</surname> <given-names>CP</given-names></string-name>, <string-name><surname>Jones-Brando</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bordon</surname> <given-names>C</given-names></string-name>, <string-name><surname>Stohler</surname> <given-names>R</given-names></string-name>, <string-name><surname>Mott</surname> <given-names>BT</given-names></string-name>, <string-name><surname>Yolken</surname> <given-names>R</given-names></string-name>, <string-name><surname>Posner</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Woodard</surname> <given-names>LE</given-names></string-name>. <article-title>Thiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii</article-title>. <source>J Med Chem</source>. <year>2010</year>;<volume>53</volume>(<issue>9</issue>):<fpage>3594</fpage>&#x2013;<lpage>3601</lpage>. PMID: <pub-id pub-id-type="pmid">20373807</pub-id>; <pub-id pub-id-type="pmcid">PMC2865576</pub-id>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Dunay</surname> <given-names>IR</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>WC</given-names></string-name>, <string-name><surname>Haynes</surname> <given-names>RK</given-names></string-name>, <string-name><surname>Sibley</surname> <given-names>LD</given-names></string-name>. <article-title>Artemisone and artemiside control acute and reactivated toxoplasmosis in the murine model</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2009</year>;<volume>53</volume>:<fpage>4450</fpage> - <lpage>4456</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Schultz</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Hencken</surname> <given-names>CP</given-names></string-name>, <string-name><surname>Woodard</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Posner</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Yolken</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Jones-Brando</surname> <given-names>L</given-names></string-name>, <string-name><surname>Carruthers</surname> <given-names>VB</given-names></string-name>. <article-title>A thiazole derivative of artemisinin moderately reduces Toxoplasma gondii cyst burden in infected mice</article-title>. <source>J Parasitol</source>. <year>2014</year>;<volume>100</volume>(<issue>4</issue>):<fpage>516</fpage>&#x2013;<lpage>521</lpage>. PMID: <pub-id pub-id-type="pmid">24524228</pub-id>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Flannery</surname> <given-names>EL</given-names></string-name>, <string-name><surname>Chatterjee</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Winzeler</surname> <given-names>EA</given-names></string-name>. <article-title>Antimalarial drug discovery - approaches and progress towards new medicines</article-title>. <source>Nat Rev Microbiol</source>. <year>2017</year>;<volume>15</volume>(<issue>9</issue>):<fpage>572</fpage>. PMID: <pub-id pub-id-type="pmid">28736448</pub-id>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Yeung</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Zou</surname> <given-names>B</given-names></string-name>, <string-name><surname>Rottmann</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lakshminarayana</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Ang</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Leong</surname> <given-names>SY</given-names></string-name>, <string-name><surname>Tan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>J</given-names></string-name>, <string-name><surname>Keller-Maerki</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fischli</surname> <given-names>C</given-names></string-name>, <string-name><surname>Goh</surname> <given-names>A</given-names></string-name>, <string-name><surname>Schmitt</surname> <given-names>EK</given-names></string-name>, <string-name><surname>Krastel</surname> <given-names>P</given-names></string-name>, <string-name><surname>Francotte</surname> <given-names>E</given-names></string-name>, <string-name><surname>Kuhen</surname> <given-names>K</given-names></string-name>, <string-name><surname>Plouffe</surname> <given-names>D</given-names></string-name>, <string-name><surname>Henson</surname> <given-names>K</given-names></string-name>, <string-name><surname>Wagner</surname> <given-names>T</given-names></string-name>, <string-name><surname>Winzeler</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Petersen</surname> <given-names>F</given-names></string-name>, <string-name><surname>Brun</surname> <given-names>R</given-names></string-name>, <string-name><surname>Dartois</surname> <given-names>V</given-names></string-name>, <string-name><surname>Diagana</surname> <given-names>TT</given-names></string-name>, <string-name><surname>Keller</surname> <given-names>TH</given-names></string-name>. <article-title>Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria</article-title>. <source>J Med Chem</source>. <year>2010</year>;<volume>53</volume>(<issue>14</issue>):<fpage>5155</fpage>&#x2013;<lpage>5164</lpage>. PMID: <pub-id pub-id-type="pmid">20568778</pub-id>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>van Pelt-Koops</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Pett</surname> <given-names>HE</given-names></string-name>, <string-name><surname>Graumans</surname> <given-names>W</given-names></string-name>, <string-name><surname>van der Vegte-Bolmer</surname> <given-names>M</given-names></string-name>, <string-name><surname>van Gemert</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Rottmann</surname> <given-names>M</given-names></string-name>, <string-name><surname>Yeung</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Diagana</surname> <given-names>TT</given-names></string-name>, <string-name><surname>Sauerwein</surname> <given-names>RW</given-names></string-name>. <article-title>The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2012</year>;<volume>56</volume>(<issue>7</issue>):<fpage>3544</fpage>&#x2013;<lpage>3548</lpage>. PMID: <pub-id pub-id-type="pmid">22508309</pub-id>; <pub-id pub-id-type="pmcid">PMC3393464</pub-id>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Rottmann</surname> <given-names>M</given-names></string-name>, <string-name><surname>McNamara</surname> <given-names>C</given-names></string-name>, <string-name><surname>Yeung</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Zou</surname> <given-names>B</given-names></string-name>, <string-name><surname>Russell</surname> <given-names>B</given-names></string-name>, <string-name><surname>Seitz</surname> <given-names>P</given-names></string-name>, <string-name><surname>Plouffe</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Dharia</surname> <given-names>NV</given-names></string-name>, <string-name><surname>Tan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Spencer</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Gonzalez-Paez</surname> <given-names>GE</given-names></string-name>, <string-name><surname>Lakshminarayana</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Goh</surname> <given-names>A</given-names></string-name>, <string-name><surname>Suwanarusk</surname> <given-names>R</given-names></string-name>, <string-name><surname>Jegla</surname> <given-names>T</given-names></string-name>, <string-name><surname>Schmitt</surname> <given-names>EK</given-names></string-name>, <string-name><surname>Beck</surname> <given-names>HP</given-names></string-name>, <string-name><surname>Brun</surname> <given-names>R</given-names></string-name>, <string-name><surname>Nosten</surname> <given-names>F</given-names></string-name>, <string-name><surname>Renia</surname> <given-names>L</given-names></string-name>, <string-name><surname>Dartois</surname> <given-names>V</given-names></string-name>, <string-name><surname>Keller</surname> <given-names>TH</given-names></string-name>, <string-name><surname>Fidock</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Winzeler</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Diagana</surname> <given-names>TT</given-names></string-name>. <article-title>Spiroindolones, a potent compound class for the treatment of malaria</article-title>. <source>Science</source>. <year>2010</year>;<volume>329</volume>(<issue>5996</issue>):<fpage>1175</fpage>&#x2013;<lpage>1180</lpage>. PMID: <pub-id pub-id-type="pmid">20813948</pub-id>; <pub-id pub-id-type="pmcid">PMC3050001</pub-id>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Spillman</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Allen</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>McNamara</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Yeung</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Winzeler</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Diagana</surname> <given-names>TT</given-names></string-name>, <string-name><surname>Kirk</surname> <given-names>K</given-names></string-name>. <article-title>Na(&#x002B;) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials</article-title>. <source>Cell Host Microbe</source>. <year>2013</year>;<volume>13</volume>(<issue>2</issue>):<fpage>227</fpage>&#x2013;<lpage>237</lpage>. PMID: <pub-id pub-id-type="pmid">23414762</pub-id>; <pub-id pub-id-type="pmcid">PMC3574224</pub-id>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Van Voorhis</surname> <given-names>WC</given-names></string-name>, <string-name><surname>Adams</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Adelfio</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ahyong</surname> <given-names>V</given-names></string-name>, <string-name><surname>Akabas</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Alano</surname> <given-names>P</given-names></string-name>, <string-name><surname>Alday</surname> <given-names>A</given-names></string-name>, <string-name><surname>Aleman Resto</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Alsibaee</surname> <given-names>A</given-names></string-name>, <string-name><surname>Alzualde</surname> <given-names>A</given-names></string-name>, <string-name><surname>Andrews</surname> <given-names>KT</given-names></string-name>, <string-name><surname>Avery</surname> <given-names>SV</given-names></string-name>, <string-name><surname>Avery</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Ayong</surname> <given-names>L</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>M</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ben Mamoun</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bhatia</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bickle</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Bounaadja</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bowling</surname> <given-names>T</given-names></string-name>, <string-name><surname>Bosch</surname> <given-names>J</given-names></string-name>, <string-name><surname>Boucher</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Boyom</surname> <given-names>FF</given-names></string-name>, <string-name><surname>Brea</surname> <given-names>J</given-names></string-name>, <string-name><surname>Brennan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Burton</surname> <given-names>A</given-names></string-name>, <string-name><surname>Caffrey</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Camarda</surname> <given-names>G</given-names></string-name>, <string-name><surname>Carrasquilla</surname> <given-names>M</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>D</given-names></string-name>, <string-name><surname>Belen Cassera</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chih-Chien Cheng</surname> <given-names>K</given-names></string-name>, <string-name><surname>Chindaudomsate</surname> <given-names>W</given-names></string-name>, <string-name><surname>Chubb</surname> <given-names>A</given-names></string-name>, <string-name><surname>Colon</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Colon-Lopez</surname> <given-names>DD</given-names></string-name>, <string-name><surname>Corbett</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Crowther</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Cowan</surname> <given-names>N</given-names></string-name>, <string-name><surname>D&#x2019;Alessandro</surname> <given-names>S</given-names></string-name>, <string-name><surname>Le Dang</surname> <given-names>N</given-names></string-name>, <string-name><surname>Delves</surname> <given-names>M</given-names></string-name>, <string-name><surname>DeRisi</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Du</surname> <given-names>AY</given-names></string-name>, <string-name><surname>Duffy</surname> <given-names>S</given-names></string-name>, <string-name><surname>Abd El-Salam El-Sayed</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ferdig</surname> <given-names>MT</given-names></string-name>, <string-name><surname>Fernandez Robledo</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Fidock</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Florent</surname> <given-names>I</given-names></string-name>, <string-name><surname>Fokou</surname> <given-names>PV</given-names></string-name>, <string-name><surname>Galstian</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gamo</surname> <given-names>FJ</given-names></string-name>, <string-name><surname>Gokool</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gold</surname> <given-names>B</given-names></string-name>, <string-name><surname>Golub</surname> <given-names>T</given-names></string-name>, <string-name><surname>Goldgof</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Guha</surname> <given-names>R</given-names></string-name>, <string-name><surname>Guiguemde</surname> <given-names>WA</given-names></string-name>, <string-name><surname>Gural</surname> <given-names>N</given-names></string-name>, <string-name><surname>Guy</surname> <given-names>RK</given-names></string-name>, <string-name><surname>Hansen</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Hanson</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Hemphill</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hooft van Huijsduijnen</surname> <given-names>R</given-names></string-name>, <string-name><surname>Horii</surname> <given-names>T</given-names></string-name>, <string-name><surname>Horrocks</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hughes</surname> <given-names>TB</given-names></string-name>, <string-name><surname>Huston</surname> <given-names>C</given-names></string-name>, <string-name><surname>Igarashi</surname> <given-names>I</given-names></string-name>, <string-name><surname>Ingram-Sieber</surname> <given-names>K</given-names></string-name>, <string-name><surname>Itoe</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Jadhav</surname> <given-names>A</given-names></string-name>, <string-name><surname>Naranuntarat Jensen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jensen</surname> <given-names>LT</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Kaiser</surname> <given-names>A</given-names></string-name>, <string-name><surname>Keiser</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ketas</surname> <given-names>T</given-names></string-name>, <string-name><surname>Kicka</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kirk</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>VP</given-names></string-name>, <string-name><surname>Kyle</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Lafuente</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Landfear</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>N</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lehane</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Li</surname> <given-names>F</given-names></string-name>, <string-name><surname>Little</surname> <given-names>D</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Llinas</surname> <given-names>M</given-names></string-name>, <string-name><surname>Loza</surname> <given-names>MI</given-names></string-name>, <string-name><surname>Lubar</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lucantoni</surname> <given-names>L</given-names></string-name>, <string-name><surname>Lucet</surname> <given-names>I</given-names></string-name>, <string-name><surname>Maes</surname> <given-names>L</given-names></string-name>, <string-name><surname>Mancama</surname> <given-names>D</given-names></string-name>, <string-name><surname>Mansour</surname> <given-names>NR</given-names></string-name>, <string-name><surname>March</surname> <given-names>S</given-names></string-name>, <string-name><surname>McGowan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Medina Vera</surname> <given-names>I</given-names></string-name>, <string-name><surname>Meister</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mercer</surname> <given-names>L</given-names></string-name>, <string-name><surname>Mestres</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mfopa</surname> <given-names>AN</given-names></string-name>, <string-name><surname>Misra</surname> <given-names>RN</given-names></string-name>, <string-name><surname>Moon</surname> <given-names>S</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Morais Rodrigues da Costa</surname> <given-names>F</given-names></string-name>, <string-name><surname>Muller</surname> <given-names>J</given-names></string-name>, <string-name><surname>Muriana</surname> <given-names>A</given-names></string-name>, <string-name><surname>Nakazawa Hewitt</surname> <given-names>S</given-names></string-name>, <string-name><surname>Nare</surname> <given-names>B</given-names></string-name>, <string-name><surname>Nathan</surname> <given-names>C</given-names></string-name>, <string-name><surname>Narraidoo</surname> <given-names>N</given-names></string-name>, <string-name><surname>Nawaratna</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ojo</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Ortiz</surname> <given-names>D</given-names></string-name>, <string-name><surname>Panic</surname> <given-names>G</given-names></string-name>, <string-name><surname>Papadatos</surname> <given-names>G</given-names></string-name>, <string-name><surname>Parapini</surname> <given-names>S</given-names></string-name>, <string-name><surname>Patra</surname> <given-names>K</given-names></string-name>, <string-name><surname>Pham</surname> <given-names>N</given-names></string-name>, <string-name><surname>Prats</surname> <given-names>S</given-names></string-name>, <string-name><surname>Plouffe</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Poulsen</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Pradhan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Quevedo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Quinn</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Rice</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Abdo Rizk</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ruecker</surname> <given-names>A</given-names></string-name>, <string-name><surname>St Onge</surname> <given-names>R</given-names></string-name>, <string-name><surname>Salgado Ferreira</surname> <given-names>R</given-names></string-name>, <string-name><surname>Samra</surname> <given-names>J</given-names></string-name>, <string-name><surname>Robinett</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Schlecht</surname> <given-names>U</given-names></string-name>, <string-name><surname>Schmitt</surname> <given-names>M</given-names></string-name>, <string-name><surname>Silva Villela</surname> <given-names>F</given-names></string-name>, <string-name><surname>Silvestrini</surname> <given-names>F</given-names></string-name>, <string-name><surname>Sinden</surname> <given-names>R</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Soldati</surname> <given-names>T</given-names></string-name>, <string-name><surname>Spitzmuller</surname> <given-names>A</given-names></string-name>, <string-name><surname>Stamm</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Sullivan</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Sullivan</surname> <given-names>W</given-names></string-name>, <string-name><surname>Suresh</surname> <given-names>S</given-names></string-name>, <string-name><surname>Suzuki</surname> <given-names>BM</given-names></string-name>, <string-name><surname>Suzuki</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Swamidass</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Taramelli</surname> <given-names>D</given-names></string-name>, <string-name><surname>Tchokouaha</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Theron</surname> <given-names>A</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>D</given-names></string-name>, <string-name><surname>Tonissen</surname> <given-names>KF</given-names></string-name>, <string-name><surname>Townson</surname> <given-names>S</given-names></string-name>, <string-name><surname>Tripathi</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Trofimov</surname> <given-names>V</given-names></string-name>, <string-name><surname>Udenze</surname> <given-names>KO</given-names></string-name>, <string-name><surname>Ullah</surname> <given-names>I</given-names></string-name>, <string-name><surname>Vallieres</surname> <given-names>C</given-names></string-name>, <string-name><surname>Vigil</surname> <given-names>E</given-names></string-name>, <string-name><surname>Vinetz</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Voong Vinh</surname> <given-names>P</given-names></string-name>, <string-name><surname>Vu</surname> <given-names>H</given-names></string-name>, <string-name><surname>Watanabe</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Weatherby</surname> <given-names>K</given-names></string-name>, <string-name><surname>White</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Wilks</surname> <given-names>AF</given-names></string-name>, <string-name><surname>Winzeler</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Wojcik</surname> <given-names>E</given-names></string-name>, <string-name><surname>Wree</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>W</given-names></string-name>, <string-name><surname>Yokoyama</surname> <given-names>N</given-names></string-name>, <string-name><surname>Zollo</surname> <given-names>PH</given-names></string-name>, <string-name><surname>Abla</surname> <given-names>N</given-names></string-name>, <string-name><surname>Blasco</surname> <given-names>B</given-names></string-name>, <string-name><surname>Burrows</surname> <given-names>J</given-names></string-name>, <string-name><surname>Laleu</surname> <given-names>B</given-names></string-name>, <string-name><surname>Leroy</surname> <given-names>D</given-names></string-name>, <string-name><surname>Spangenberg</surname> <given-names>T</given-names></string-name>, <string-name><surname>Wells</surname> <given-names>T</given-names></string-name>, <string-name><surname>Willis</surname> <given-names>PA</given-names></string-name>. <article-title>Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond</article-title>. <source>PLoS Pathog</source>. <year>2016</year>;<volume>12</volume>(<issue>7</issue>):<fpage>e1005763</fpage>. PMID: <pub-id pub-id-type="pmid">27467575</pub-id>; <pub-id pub-id-type="pmcid">PMC4965013</pub-id>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Boyom</surname> <given-names>FF</given-names></string-name>, <string-name><surname>Fokou</surname> <given-names>PV</given-names></string-name>, <string-name><surname>Tchokouaha</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Spangenberg</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mfopa</surname> <given-names>AN</given-names></string-name>, <string-name><surname>Kouipou</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Mbouna</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Donfack</surname> <given-names>VF</given-names></string-name>, <string-name><surname>Zollo</surname> <given-names>PH</given-names></string-name>. <article-title>Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>(<issue>10</issue>):<fpage>5848</fpage>&#x2013;<lpage>5854</lpage>. PMID: <pub-id pub-id-type="pmid">25049259</pub-id>; <pub-id pub-id-type="pmcid">PMC4187973</pub-id>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Doggett</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Nilsen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Forquer</surname> <given-names>I</given-names></string-name>, <string-name><surname>Wegmann</surname> <given-names>KW</given-names></string-name>, <string-name><surname>Jones-Brando</surname> <given-names>L</given-names></string-name>, <string-name><surname>Yolken</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Bordon</surname> <given-names>C</given-names></string-name>, <string-name><surname>Charman</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Katneni</surname> <given-names>K</given-names></string-name>, <string-name><surname>Schultz</surname> <given-names>T</given-names></string-name>, <string-name><surname>Burrows</surname> <given-names>JN</given-names></string-name>, <string-name><surname>Hinrichs</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Meunier</surname> <given-names>B</given-names></string-name>, <string-name><surname>Carruthers</surname> <given-names>VB</given-names></string-name>, <string-name><surname>Riscoe</surname> <given-names>MK</given-names></string-name>. <article-title>Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2012</year>;<volume>109</volume>(<issue>39</issue>):<fpage>15936</fpage>&#x2013;<lpage>15941</lpage>. PMID: <pub-id pub-id-type="pmid">23019377</pub-id>; <pub-id pub-id-type="doi">3465437</pub-id>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Kovacs</surname> <given-names>JA</given-names></string-name>. <article-title>Efficacy of atovoquone in treatment of toxoplasmosis in AIDS patients</article-title>. <source>Lancet</source>. <year>1992</year>;<volume>340</volume>:<fpage>637</fpage>&#x2013;<lpage>638</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Subramanian</surname> <given-names>G</given-names></string-name>, <string-name><surname>Belekar</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Shukla</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tong</surname> <given-names>JX</given-names></string-name>, <string-name><surname>Sinha</surname> <given-names>A</given-names></string-name>, <string-name><surname>Chu</surname> <given-names>TTT</given-names></string-name>, <string-name><surname>Kulkarni</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Preiser</surname> <given-names>PR</given-names></string-name>, <string-name><surname>Reddy</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Tan</surname> <given-names>KSW</given-names></string-name>, <string-name><surname>Shanmugam</surname> <given-names>D</given-names></string-name>, <string-name><surname>Chandramohanadas</surname> <given-names>R</given-names></string-name>. <article-title>Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules</article-title>. <source>mSphere</source>. <year>2018</year>;<volume>3</volume>(<issue>1</issue>). PMID: <pub-id pub-id-type="pmid">29359192</pub-id>; <pub-id pub-id-type="pmcid">PMC5770543</pub-id>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Spalenka</surname> <given-names>J</given-names></string-name>, <string-name><surname>Escotte-Binet</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bakiri</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hubert</surname> <given-names>J</given-names></string-name>, <string-name><surname>Renault</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Velard</surname> <given-names>F</given-names></string-name>, <string-name><surname>Duchateau</surname> <given-names>S</given-names></string-name>, <string-name><surname>Aubert</surname> <given-names>D</given-names></string-name>, <string-name><surname>Huguenin</surname> <given-names>A</given-names></string-name>, <string-name><surname>Villena</surname> <given-names>I</given-names></string-name>. <article-title>Discovery of New Inhibitors of Toxoplasma gondii via the Pathogen Box</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2018</year>;<volume>62</volume>(<issue>2</issue>). PMID: <pub-id pub-id-type="pmid">29133550</pub-id>; <pub-id pub-id-type="pmcid">PMC5786798</pub-id>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Wells</surname> <given-names>TN</given-names></string-name>, <string-name><surname>Hooft van Huijsduijnen</surname> <given-names>R</given-names></string-name>, <string-name><surname>Van Voorhis</surname> <given-names>WC</given-names></string-name>. <article-title>Malaria medicines: a glass half full&#x003F;</article-title> <source>Nat Rev Drug Discov</source>. <year>2015</year>;<volume>14</volume>(<issue>6</issue>):<fpage>424</fpage>&#x2013;<lpage>442</lpage>. PMID: <pub-id pub-id-type="pmid">26000721</pub-id>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Chio</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Queener</surname> <given-names>SF</given-names></string-name>. <article-title>Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1993</year>;<volume>37</volume>(<issue>9</issue>):<fpage>1914</fpage>&#x2013;<lpage>1923</lpage>. PMID: <pub-id pub-id-type="pmid">8239605</pub-id>; <pub-id pub-id-type="pmcid">PMC188092</pub-id>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Meneceur</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bouldouyre</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Aubert</surname> <given-names>D</given-names></string-name>, <string-name><surname>Villena</surname> <given-names>I</given-names></string-name>, <string-name><surname>Menotti</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sauvage</surname> <given-names>V</given-names></string-name>, <string-name><surname>Garin</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Derouin</surname> <given-names>F</given-names></string-name>. <article-title>In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2008</year>;<volume>52</volume>(<issue>4</issue>):<fpage>1269</fpage>&#x2013;<lpage>1277</lpage>. PMID: <pub-id pub-id-type="pmid">18212105</pub-id>; <pub-id pub-id-type="doi">2292506</pub-id>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Harris</surname> <given-names>C</given-names></string-name>, <string-name><surname>Salgo</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Tanowitz</surname> <given-names>HB</given-names></string-name>, <string-name><surname>Wittner</surname> <given-names>M</given-names></string-name>. <article-title>In vitro assessment of antimicrobial agents against <italic>Toxoplasma gondii</italic></article-title>. <source>J Infect Dis</source>. <year>1988</year>;<volume>157</volume>:<fpage>14</fpage>&#x2013;<lpage>22</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Stahl</surname> <given-names>W</given-names></string-name>, <string-name><surname>Collins</surname> <given-names>DN</given-names></string-name>, <string-name><surname>Benitez</surname> <given-names>P</given-names></string-name>, <string-name><surname>Turek</surname> <given-names>G</given-names></string-name>, <string-name><surname>Gaafar</surname> <given-names>H</given-names></string-name>. <article-title>Toxoplasma gondii: disease patterns in mice treated with the folate antagonist methotrexate</article-title>. <source>Exp Parasitol</source>. <year>1976</year>;<volume>39</volume>(<issue>1</issue>):<fpage>135</fpage>&#x2013;<lpage>142</lpage>. PMID: <pub-id pub-id-type="pmid">1253880</pub-id>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Holfels</surname> <given-names>E</given-names></string-name>, <string-name><surname>McAuley</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mack</surname> <given-names>D</given-names></string-name>, <string-name><surname>Milhous</surname> <given-names>WK</given-names></string-name>, <string-name><surname>McLeod</surname> <given-names>R</given-names></string-name>. <article-title><italic>In vitro</italic> effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on <italic>Toxoplasma gondii</italic></article-title>. <source>Antimicrob Agents Chem</source>. <year>1994</year>;<volume>38</volume>:<fpage>1392</fpage>&#x2013;<lpage>1396</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Reynolds</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Roos</surname> <given-names>DS</given-names></string-name>. <article-title>A biochemical and genetic model for parasite resistance to antifolates. Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum</article-title>. <source>J Biol Chem</source>. <year>1998</year>;<volume>273</volume>(<issue>6</issue>):<fpage>3461</fpage>&#x2013;<lpage>3469</lpage>. PMID: <pub-id pub-id-type="pmid">9452469</pub-id>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Belal</surname> <given-names>US</given-names></string-name>, <string-name><surname>Norose</surname> <given-names>K</given-names></string-name>, <string-name><surname>Mohamed</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Sekine</surname> <given-names>S</given-names></string-name>, <string-name><surname>Nukaga</surname> <given-names>T</given-names></string-name>, <string-name><surname>Ito</surname> <given-names>K</given-names></string-name>, <string-name><surname>Abdellatif</surname> <given-names>MZ</given-names></string-name>, <string-name><surname>Abdelgelil</surname> <given-names>NH</given-names></string-name>, <string-name><surname>Yano</surname> <given-names>A</given-names></string-name>. <article-title>Quantitative assessment of the effects of sulfamethoxazole on Toxoplasma gondii loads in susceptible WT C57BL/6 mice as an immunocompetent host model</article-title>. <source>Parasitol Int</source>. <year>2016</year>;<volume>65</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>4</lpage>. PMID: <pub-id pub-id-type="pmid">26384856</pub-id>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Brun-Pascaud</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chau</surname> <given-names>F</given-names></string-name>, <string-name><surname>Garry</surname> <given-names>L</given-names></string-name>, <string-name><surname>Jacobus</surname> <given-names>D</given-names></string-name>, <string-name><surname>Derouin</surname> <given-names>F</given-names></string-name>, <string-name><surname>Girard</surname> <given-names>PM</given-names></string-name>. <article-title>Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1996</year>;<volume>40</volume>(<issue>9</issue>):<fpage>2067</fpage>&#x2013;<lpage>2070</lpage>. PMID: <pub-id pub-id-type="pmid">8878582</pub-id>; <pub-id pub-id-type="pmcid">PMC163474</pub-id>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Derouin</surname> <given-names>F</given-names></string-name>, <string-name><surname>Almadany</surname> <given-names>R</given-names></string-name>, <string-name><surname>Chau</surname> <given-names>F</given-names></string-name>, <string-name><surname>Rouveix</surname> <given-names>B</given-names></string-name>, <string-name><surname>Pocidalo</surname> <given-names>JJ</given-names></string-name>. <article-title>Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1992</year>;<volume>36</volume>(<issue>5</issue>):<fpage>997</fpage>&#x2013;<lpage>1001</lpage>. PMID: <pub-id pub-id-type="pmid">1324642</pub-id>; <pub-id pub-id-type="pmcid">PMC188824</pub-id>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Chang</surname> <given-names>HR</given-names></string-name>, <string-name><surname>Comte</surname> <given-names>R</given-names></string-name>, <string-name><surname>Pech&#x00E9;re</surname> <given-names>JC</given-names></string-name>. <article-title>In vitro and in vivo efects of doxycycline on <italic>Toxoplasma gondii</italic></article-title>. <source>Anti Microb Agents Chemother</source>. <year>1990</year>;<volume>34</volume>:<fpage>775</fpage>&#x2013;<lpage>780</lpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Berg-Candolfi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Candolfi</surname> <given-names>E</given-names></string-name>. <article-title>Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection</article-title>. <source>Int J Parasitol</source>. <year>1996</year>;<volume>26</volume>(<issue>11</issue>):<fpage>1321</fpage>&#x2013;<lpage>1323</lpage>. PMID: <pub-id pub-id-type="pmid">9024879</pub-id>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Djurkovic-Djakovic</surname> <given-names>O</given-names></string-name>, <string-name><surname>Milenkovic</surname> <given-names>V</given-names></string-name>, <string-name><surname>Nikolic</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bobic</surname> <given-names>B</given-names></string-name>, <string-name><surname>Grujic</surname> <given-names>J</given-names></string-name>. <article-title>Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii</article-title>. <source>J Antimicrob Chemother</source>. <year>2002</year>;<volume>50</volume>(<issue>6</issue>):<fpage>981</fpage>&#x2013;<lpage>987</lpage>. PMID: <pub-id pub-id-type="pmid">12461021</pub-id>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Djurkovic-Djakovic</surname> <given-names>O</given-names></string-name>, <string-name><surname>Nikolic</surname> <given-names>T</given-names></string-name>, <string-name><surname>Robert-Gangneux</surname> <given-names>F</given-names></string-name>, <string-name><surname>Bobic</surname> <given-names>B</given-names></string-name>, <string-name><surname>Nikolic</surname> <given-names>A</given-names></string-name>. <article-title>Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1999</year>;<volume>43</volume>(<issue>9</issue>):<fpage>2240</fpage>&#x2013;<lpage>2244</lpage>. PMID: <pub-id pub-id-type="pmid">10471572</pub-id>; <pub-id pub-id-type="pmcid">PMC89454</pub-id>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Ribeiro</surname> <given-names>M</given-names></string-name>, <string-name><surname>Franco</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Lopes-Maria</surname> <given-names>JB</given-names></string-name>, <string-name><surname>Angeloni</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Barbosa</surname> <given-names>BF</given-names></string-name>, <string-name><surname>Gomes</surname> <given-names>AO</given-names></string-name>, <string-name><surname>Castro</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Silva</surname> <given-names>RJD</given-names></string-name>, <string-name><surname>Oliveira</surname> <given-names>FC</given-names></string-name>, <string-name><surname>Milian</surname> <given-names>ICB</given-names></string-name>, <string-name><surname>Martins-Filho</surname> <given-names>OA</given-names></string-name>, <string-name><surname>Ietta</surname> <given-names>F</given-names></string-name>, <string-name><surname>Mineo</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Ferro</surname> <given-names>EAV</given-names></string-name>. <article-title>Azithromycin treatment is able to control the infection by two genotypes of Toxoplasma gondii in human trophoblast BeWo cells</article-title>. <source>Exp Parasitol</source>. <year>2017</year>;<volume>181</volume>:<fpage>111</fpage>&#x2013;<lpage>118</lpage>. PMID: <pub-id pub-id-type="pmid">28803905</pub-id>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Camps</surname> <given-names>M</given-names></string-name>, <string-name><surname>Arrizabalaga</surname> <given-names>G</given-names></string-name>, <string-name><surname>Boothroyd</surname> <given-names>J</given-names></string-name>. <article-title>An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii</article-title>. <source>Mol Microbiol</source>. <year>2002</year>;<volume>43</volume>(<issue>5</issue>):<fpage>1309</fpage>&#x2013;<lpage>1318</lpage>. PMID: <pub-id pub-id-type="pmid">11918815</pub-id>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>Slimings</surname> <given-names>C</given-names></string-name>, <string-name><surname>Riley</surname> <given-names>TV</given-names></string-name>. <article-title>Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis</article-title>. <source>J Antimicrob Chemother</source>. <year>2014</year>;<volume>69</volume>(<issue>4</issue>):<fpage>881</fpage>&#x2013;<lpage>891</lpage>. PMID: <pub-id pub-id-type="pmid">24324224</pub-id>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Alday</surname> <given-names>PH</given-names></string-name>, <string-name><surname>Bruzual</surname> <given-names>I</given-names></string-name>, <string-name><surname>Nilsen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pou</surname> <given-names>S</given-names></string-name>, <string-name><surname>Winter</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ben Mamoun</surname> <given-names>C</given-names></string-name>, <string-name><surname>Riscoe</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Doggett</surname> <given-names>JS</given-names></string-name>. <article-title>Genetic Evidence for Cytochrome b Qi Site Inhibition by 4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2017</year>;<volume>61</volume>(<issue>2</issue>). PMID: <pub-id pub-id-type="pmid">27919897</pub-id>; <pub-id pub-id-type="pmcid">PMC5278733</pub-id>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>McFadden</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Tomavo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Berry</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Boothroyd</surname> <given-names>JC</given-names></string-name>. <article-title>Characterization of cytochrome b from <italic>Toxoplasma gondii</italic> and Qo domain mutations as a mechanism of atovaquone<sup>-</sup> resistance</article-title>. <source>Mol Biochem Parasitol</source>. <year>2000</year>;<volume>108</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>12</lpage>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Dunay</surname> <given-names>IR</given-names></string-name>, <string-name><surname>Heimesaat</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Bushrab</surname> <given-names>FN</given-names></string-name>, <string-name><surname>Muller</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Stocker</surname> <given-names>H</given-names></string-name>, <string-name><surname>Arasteh</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kurowski</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fitzner</surname> <given-names>R</given-names></string-name>, <string-name><surname>Borner</surname> <given-names>K</given-names></string-name>, <string-name><surname>Liesenfeld</surname> <given-names>O</given-names></string-name>. <article-title>Atovaquone maintenance therapy prevents reactivation of toxopasmic encepahalitis in the murine model of reactivated toxoplasmosis</article-title>. <source>Antimicrob Agents Chem</source>. <year>2004</year>;<volume>48</volume>:<fpage>4848</fpage>&#x2013;<lpage>4854</lpage>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Gajurel</surname> <given-names>K</given-names></string-name>, <string-name><surname>Gomez</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Dhakal</surname> <given-names>R</given-names></string-name>, <string-name><surname>Vogel</surname> <given-names>H</given-names></string-name>, <string-name><surname>Montoya</surname> <given-names>JG</given-names></string-name>. <article-title>Failure of primary atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipients</article-title>. <source>Transpl Infect Dis</source>. <year>2016</year>;<volume>18</volume>(<issue>3</issue>):<fpage>446</fpage>&#x2013;<lpage>452</lpage>. PMID: <pub-id pub-id-type="pmid">27016655</pub-id>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>McPhillie</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>El Bissati</surname> <given-names>K</given-names></string-name>, <string-name><surname>Dubey</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lorenzi</surname> <given-names>H</given-names></string-name>, <string-name><surname>Capper</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lukens</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Hickman</surname> <given-names>M</given-names></string-name>, <string-name><surname>Muench</surname> <given-names>S</given-names></string-name>, <string-name><surname>Verma</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Weber</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Wheeler</surname> <given-names>K</given-names></string-name>, <string-name><surname>Gordon</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sanders</surname> <given-names>J</given-names></string-name>, <string-name><surname>Moulton</surname> <given-names>H</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>TK</given-names></string-name>, <string-name><surname>He</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Santos</surname> <given-names>T</given-names></string-name>, <string-name><surname>Woods</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>P</given-names></string-name>, <string-name><surname>Donkin</surname> <given-names>D</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>E</given-names></string-name>, <string-name><surname>Fraczek</surname> <given-names>L</given-names></string-name>, <string-name><surname>Lykins</surname> <given-names>J</given-names></string-name>, <string-name><surname>Esaa</surname> <given-names>F</given-names></string-name>, <string-name><surname>Alibana-Clouser</surname> <given-names>F</given-names></string-name>, <string-name><surname>Dovgin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Weiss</surname> <given-names>L</given-names></string-name>, <string-name><surname>Brasseur</surname> <given-names>G</given-names></string-name>, <string-name><surname>Wirth</surname> <given-names>D</given-names></string-name>, <string-name><surname>Kent</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hood</surname> <given-names>L</given-names></string-name>, <string-name><surname>Meunieur</surname> <given-names>B</given-names></string-name>, <string-name><surname>Roberts</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Hasnain</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Antonyuk</surname> <given-names>SV</given-names></string-name>, <string-name><surname>Fishwick</surname> <given-names>C</given-names></string-name>, <string-name><surname>McLeod</surname> <given-names>R</given-names></string-name>. <article-title>New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>29179</fpage>. PMID: <pub-id pub-id-type="pmid">27412848</pub-id>; <pub-id pub-id-type="pmcid">PMC4944145</pub-id>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><string-name><surname>Frueh</surname> <given-names>L</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Mather</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Pou</surname> <given-names>S</given-names></string-name>, <string-name><surname>Nilsen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Winter</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Forquer</surname> <given-names>IP</given-names></string-name>, <string-name><surname>Pershing</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>LH</given-names></string-name>, <string-name><surname>Smilkstein</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Caridha</surname> <given-names>D</given-names></string-name>, <string-name><surname>Koop</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Campbell</surname> <given-names>RF</given-names></string-name>, <string-name><surname>Sciotti</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Kreishman-Deitrick</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kelly</surname> <given-names>JX</given-names></string-name>, <string-name><surname>Vesely</surname> <given-names>B</given-names></string-name>, <string-name><surname>Vaidya</surname> <given-names>AB</given-names></string-name>, <string-name><surname>Riscoe</surname> <given-names>MK</given-names></string-name>. <article-title>Alkoxycarbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria</article-title>. <source>ACS Infect Dis</source>. <year>2017</year>;<volume>3</volume>(<issue>10</issue>):<fpage>728</fpage>&#x2013;<lpage>735</lpage>. PMID: <pub-id pub-id-type="pmid">28927276</pub-id>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><string-name><surname>Sullivan</surname> <given-names>DJ</given-names>, <suffix>Jr.</suffix></string-name>, <string-name><surname>Matile</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ridley</surname> <given-names>RG</given-names></string-name>, <string-name><surname>Goldberg</surname> <given-names>DE</given-names></string-name>. <article-title>A common mechanism for blockade of heme polymerization by antimalarial quinolines</article-title>. <source>J Biol Chem</source>. <year>1998</year>;<volume>273</volume>(<issue>47</issue>):<fpage>31103</fpage>&#x2013;<lpage>31107</lpage>. PMID: <pub-id pub-id-type="pmid">9813011</pub-id>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><string-name><surname>Tekwani</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Walker</surname> <given-names>LA</given-names></string-name>. <article-title>8-Aminoquinolines: future role as antiprotozoal drugs</article-title>. <source>Curr Opin Infect Dis</source>. <year>2006</year>;<volume>19</volume>(<issue>6</issue>):<fpage>623</fpage>&#x2013;<lpage>631</lpage>. PMID: <pub-id pub-id-type="pmid">17075340</pub-id>.</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><string-name><surname>Rudrapal</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chetia</surname> <given-names>D</given-names></string-name>. <article-title>Endoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffold</article-title>. <source>Drug Des Devel Ther</source>. <year>2016</year>;<volume>10</volume>:<fpage>3575</fpage>&#x2013;<lpage>3590</lpage>. PMID: <pub-id pub-id-type="pmid">27843298</pub-id>; <pub-id pub-id-type="pmcid">PMC5098533</pub-id>.</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><string-name><surname>Spillman</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Kirk</surname> <given-names>K</given-names></string-name>. <article-title>The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs</article-title>. <source>Int J Parasitol Drugs Drug Resist</source>. <year>2015</year>;<volume>5</volume>(<issue>3</issue>):<fpage>149</fpage>&#x2013;<lpage>162</lpage>. PMID: <pub-id pub-id-type="pmid">26401486</pub-id>; <pub-id pub-id-type="pmcid">PMC4559606</pub-id>.</mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Fomovska</surname> <given-names>A</given-names></string-name>, <string-name><surname>Muench</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lai</surname> <given-names>BS</given-names></string-name>, <string-name><surname>Mui</surname> <given-names>E</given-names></string-name>, <string-name><surname>McLeod</surname> <given-names>R</given-names></string-name>. <article-title>Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>(<issue>3</issue>):<fpage>1789</fpage>&#x2013;<lpage>1792</lpage>. PMID: <pub-id pub-id-type="pmid">24366743</pub-id>; <pub-id pub-id-type="pmcid">PMC3957861</pub-id>.</mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><string-name><surname>Vaidya</surname> <given-names>AB</given-names></string-name>, <string-name><surname>Morrisey</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Das</surname> <given-names>S</given-names></string-name>, <string-name><surname>Daly</surname> <given-names>TM</given-names></string-name>, <string-name><surname>Otto</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Spillman</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Wyvratt</surname> <given-names>M</given-names></string-name>, <string-name><surname>Siegl</surname> <given-names>P</given-names></string-name>, <string-name><surname>Marfurt</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wirjanata</surname> <given-names>G</given-names></string-name>, <string-name><surname>Sebayang</surname> <given-names>BF</given-names></string-name>, <string-name><surname>Price</surname> <given-names>RN</given-names></string-name>, <string-name><surname>Chatterjee</surname> <given-names>A</given-names></string-name>, <string-name><surname>Nagle</surname> <given-names>A</given-names></string-name>, <string-name><surname>Stasiak</surname> <given-names>M</given-names></string-name>, <string-name><surname>Charman</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Angulo-Barturen</surname> <given-names>I</given-names></string-name>, <string-name><surname>Ferrer</surname> <given-names>S</given-names></string-name>, <string-name><surname>Belen Jimenez-Diaz</surname> <given-names>M</given-names></string-name>, <string-name><surname>Martinez</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Gamo</surname> <given-names>FJ</given-names></string-name>, <string-name><surname>Avery</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Ruecker</surname> <given-names>A</given-names></string-name>, <string-name><surname>Delves</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kirk</surname> <given-names>K</given-names></string-name>, <string-name><surname>Berriman</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kortagere</surname> <given-names>S</given-names></string-name>, <string-name><surname>Burrows</surname> <given-names>J</given-names></string-name>, <string-name><surname>Fan</surname> <given-names>E</given-names></string-name>, <string-name><surname>Bergman</surname> <given-names>LW</given-names></string-name>. <article-title>Pyrazoleamide compounds are potent antimalarials that target Na&#x002B; homeostasis in intraerythrocytic Plasmodium falciparum</article-title>. <source>Nature communications</source>. <year>2014</year>;<volume>5</volume>:<fpage>5521</fpage>. PMID: <pub-id pub-id-type="pmid">25422853</pub-id>; <pub-id pub-id-type="pmcid">PMC4263321</pub-id>.</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><string-name><surname>White</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Duong</surname> <given-names>TT</given-names></string-name>, <string-name><surname>Uthaisin</surname> <given-names>C</given-names></string-name>, <string-name><surname>Nosten</surname> <given-names>F</given-names></string-name>, <string-name><surname>Phyo</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Hanboonkunupakarn</surname> <given-names>B</given-names></string-name>, <string-name><surname>Pukrittayakamee</surname> <given-names>S</given-names></string-name>, <string-name><surname>Jittamala</surname> <given-names>P</given-names></string-name>, <string-name><surname>Chuthasmit</surname> <given-names>K</given-names></string-name>, <string-name><surname>Cheung</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Feng</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Li</surname> <given-names>R</given-names></string-name>, <string-name><surname>Magnusson</surname> <given-names>B</given-names></string-name>, <string-name><surname>Sultan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wieser</surname> <given-names>D</given-names></string-name>, <string-name><surname>Xun</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>R</given-names></string-name>, <string-name><surname>Diagana</surname> <given-names>TT</given-names></string-name>, <string-name><surname>Pertel</surname> <given-names>P</given-names></string-name>, <string-name><surname>Leong</surname> <given-names>FJ</given-names></string-name>. <article-title>Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>(<issue>12</issue>):<fpage>1152</fpage>&#x2013;<lpage>1160</lpage>. PMID: <pub-id pub-id-type="pmid">27653565</pub-id>; <pub-id pub-id-type="pmcid">PMC5142602</pub-id>.</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><string-name><surname>Dembele</surname> <given-names>L</given-names></string-name>, <string-name><surname>Ang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Chavchich</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bonamy</surname> <given-names>GMC</given-names></string-name>, <string-name><surname>Selva</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>MY</given-names></string-name>, <string-name><surname>Bodenreider</surname> <given-names>C</given-names></string-name>, <string-name><surname>Yeung</surname> <given-names>BKS</given-names></string-name>, <string-name><surname>Nosten</surname> <given-names>F</given-names></string-name>, <string-name><surname>Russell</surname> <given-names>BM</given-names></string-name>, <string-name><surname>Edstein</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Straimer</surname> <given-names>J</given-names></string-name>, <string-name><surname>Fidock</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Diagana</surname> <given-names>TT</given-names></string-name>, <string-name><surname>Bifani</surname> <given-names>P</given-names></string-name>. <article-title>The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>2325</fpage>. PMID: <pub-id pub-id-type="pmid">28539634</pub-id>; <pub-id pub-id-type="pmcid">PMC5443816</pub-id>.</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><string-name><surname>Hoepfner</surname> <given-names>D</given-names></string-name>, <string-name><surname>McNamara</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Studer</surname> <given-names>C</given-names></string-name>, <string-name><surname>Riedl</surname> <given-names>R</given-names></string-name>, <string-name><surname>Aust</surname> <given-names>T</given-names></string-name>, <string-name><surname>McCormack</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Plouffe</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Meister</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schuierer</surname> <given-names>S</given-names></string-name>, <string-name><surname>Plikat</surname> <given-names>U</given-names></string-name>, <string-name><surname>Hartmann</surname> <given-names>N</given-names></string-name>, <string-name><surname>Staedtler</surname> <given-names>F</given-names></string-name>, <string-name><surname>Cotesta</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schmitt</surname> <given-names>EK</given-names></string-name>, <string-name><surname>Petersen</surname> <given-names>F</given-names></string-name>, <string-name><surname>Supek</surname> <given-names>F</given-names></string-name>, <string-name><surname>Glynne</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Tallarico</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Porter</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Fishman</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Bodenreider</surname> <given-names>C</given-names></string-name>, <string-name><surname>Diagana</surname> <given-names>TT</given-names></string-name>, <string-name><surname>Movva</surname> <given-names>NR</given-names></string-name>, <string-name><surname>Winzeler</surname> <given-names>EA</given-names></string-name>. <article-title>Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin</article-title>. <source>Cell Host Microbe</source>. <year>2012</year>;<volume>11</volume>(<issue>6</issue>):<fpage>654</fpage>&#x2013;<lpage>663</lpage>. PMID: <pub-id pub-id-type="pmid">22704625</pub-id>; <pub-id pub-id-type="pmcid">PMC3391680</pub-id>.</mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="journal"><string-name><surname>Khan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sharma</surname> <given-names>A</given-names></string-name>, <string-name><surname>Belrhali</surname> <given-names>H</given-names></string-name>, <string-name><surname>Yogavel</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sharma</surname> <given-names>A</given-names></string-name>. <article-title>Structural basis of malaria parasite lysyl-tRNA synthetase inhibition by cladosporin</article-title>. <source>J Struct Funct Genomics</source>. <year>2014</year>;<volume>15</volume>(<issue>2</issue>):<fpage>63</fpage>&#x2013;<lpage>71</lpage>. PMID: <pub-id pub-id-type="pmid">24935905</pub-id>.</mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><string-name><surname>Phillips</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Rathod</surname> <given-names>PK</given-names></string-name>. <article-title>Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy</article-title>. <source>Infect Disord Drug Targets</source>. <year>2010</year>;<volume>10</volume>(<issue>3</issue>):<fpage>226</fpage>&#x2013;<lpage>239</lpage>. PMID: <pub-id pub-id-type="pmid">20334617</pub-id>; <pub-id pub-id-type="pmcid">PMC2883174</pub-id>.</mixed-citation></ref>
<ref id="c84"><label>84.</label><mixed-citation publication-type="journal"><string-name><surname>Phillips</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Lotharius</surname> <given-names>J</given-names></string-name>, <string-name><surname>Marsh</surname> <given-names>K</given-names></string-name>, <string-name><surname>White</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dayan</surname> <given-names>A</given-names></string-name>, <string-name><surname>White</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Njoroge</surname> <given-names>JW</given-names></string-name>, <string-name><surname>El Mazouni</surname> <given-names>F</given-names></string-name>, <string-name><surname>Lao</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Kokkonda</surname> <given-names>S</given-names></string-name>, <string-name><surname>Tomchick</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Deng</surname> <given-names>X</given-names></string-name>, <string-name><surname>Laird</surname> <given-names>T</given-names></string-name>, <string-name><surname>Bhatia</surname> <given-names>SN</given-names></string-name>, <string-name><surname>March</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ng</surname> <given-names>CL</given-names></string-name>, <string-name><surname>Fidock</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Wittlin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lafuente-Monasterio</surname> <given-names>M</given-names></string-name>, <string-name><surname>Benito</surname> <given-names>FJ</given-names></string-name>, <string-name><surname>Alonso</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Martinez</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Jimenez-Diaz</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Bazaga</surname> <given-names>SF</given-names></string-name>, <string-name><surname>Angulo-Barturen</surname> <given-names>I</given-names></string-name>, <string-name><surname>Haselden</surname> <given-names>JN</given-names></string-name>, <string-name><surname>Louttit</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cui</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Sridhar</surname> <given-names>A</given-names></string-name>, <string-name><surname>Zeeman</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Kocken</surname> <given-names>C</given-names></string-name>, <string-name><surname>Sauerwein</surname> <given-names>R</given-names></string-name>, <string-name><surname>Dechering</surname> <given-names>K</given-names></string-name>, <string-name><surname>Avery</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Duffy</surname> <given-names>S</given-names></string-name>, <string-name><surname>Delves</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sinden</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ruecker</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wickham</surname> <given-names>KS</given-names></string-name>, <string-name><surname>Rochford</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gahagen</surname> <given-names>J</given-names></string-name>, <string-name><surname>Iyer</surname> <given-names>L</given-names></string-name>, <string-name><surname>Riccio</surname> <given-names>E</given-names></string-name>, <string-name><surname>Mirsalis</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bathhurst</surname> <given-names>I</given-names></string-name>, <string-name><surname>Rueckle</surname> <given-names>T</given-names></string-name>, <string-name><surname>Ding</surname> <given-names>X</given-names></string-name>, <string-name><surname>Campo</surname> <given-names>B</given-names></string-name>, <string-name><surname>Leroy</surname> <given-names>D</given-names></string-name>, <string-name><surname>Rogers</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Rathod</surname> <given-names>PK</given-names></string-name>, <string-name><surname>Burrows</surname> <given-names>JN</given-names></string-name>, <string-name><surname>Charman</surname> <given-names>SA</given-names></string-name>. <article-title>A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria</article-title>. <source>Sci Transl Med</source>. <year>2015</year>;<volume>7</volume>(<issue>296</issue>):<fpage>296ra111</fpage>. PMID: <pub-id pub-id-type="pmid">26180101</pub-id>; <pub-id pub-id-type="pmcid">PMC4539048</pub-id>.</mixed-citation></ref>
<ref id="c85"><label>85.</label><mixed-citation publication-type="journal"><string-name><surname>Hortua Triana</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Cajiao Herrera</surname> <given-names>D</given-names></string-name>, <string-name><surname>Zimmermann</surname> <given-names>BH</given-names></string-name>, <string-name><surname>Fox</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Bzik</surname> <given-names>DJ</given-names></string-name>. <article-title>Pyrimidine Pathway-Dependent and -Independent Functions of the Toxoplasma gondii Mitochondrial Dihydroorotate Dehydrogenase</article-title>. <source>Infect Immun</source>. <year>2016</year>;<volume>84</volume>(<issue>10</issue>):<fpage>2974</fpage>&#x2013;<lpage>2981</lpage>. PMID: <pub-id pub-id-type="pmid">27481247</pub-id>; <pub-id pub-id-type="pmcid">PMC5038078</pub-id>.</mixed-citation></ref>
<ref id="c86"><label>86.</label><mixed-citation publication-type="journal"><string-name><surname>Pfefferkorn</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Pfefferkorn</surname> <given-names>LC</given-names></string-name>. <article-title>Specific labeling of intracellular <italic>Toxoplasma gondii</italic> with uracil</article-title>. <source>Journal of Protozoology</source>. <year>1977</year>;<volume>24</volume>:<fpage>449</fpage>&#x2013;<lpage>453</lpage>.</mixed-citation></ref>
<ref id="c87"><label>87.</label><mixed-citation publication-type="journal"><string-name><surname>Tobin</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Knoll</surname> <given-names>LJ</given-names></string-name>. <article-title>A patatin-like protein protects Toxoplasma gondii from degradation in a nitric oxide-dependent manner</article-title>. <source>Infect Immun</source>. <year>2012</year>;<volume>80</volume>(<issue>1</issue>):<fpage>55</fpage>&#x2013;<lpage>61</lpage>. PMID: <pub-id pub-id-type="pmid">22006568</pub-id>; <pub-id pub-id-type="pmcid">PMC3255658</pub-id>.</mixed-citation></ref>
</ref-list>
</back>
</article>